<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">KmFZjtxCLnYJD8ndsnKHt3h</article-id>
      <article-id pub-id-type="other">00021</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2010000100021</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(10)09400121</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2010000100021</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigo de Revis&#227;o</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Altera&#231;&#245;es ecocardiogr&#225;ficas em pacientes com insufici&#234;ncia renal cr&#244;nica em programa de hemodi&#225;lise</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Barberato</surname>
            <given-names>Silvio Henrique</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pecoits-Filho</surname>
            <given-names>Roberto</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">Curitiba</named-content>
          <named-content content-type="state">Paran&#225;</named-content>
        </addr-line>
        <institution content-type="orgname">Pontif&#237;cia Universidade Cat&#243;lica do Paran&#225;</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>01</month>
        <year>2010</year>
      </pub-date>
      <volume>94</volume>
      <issue>1</issue>
      <fpage>140</fpage>
      <lpage>146</lpage>
      <history>
        <date date-type="received">
          <day>26</day>
          <month>07</month>
          <year>2008</year>
        </date>
        <date date-type="accepted">
          <day>13</day>
          <month>10</month>
          <year>2008</year>
        </date>
        <date date-type="rev-recd">
          <day>12</day>
          <month>09</month>
          <year>2008</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Altera&#231;&#245;es de estrutura e fun&#231;&#227;o card&#237;acas detectadas pela ecocardiografia s&#227;o comuns em pacientes com doen&#231;a renal cr&#244;nica em hemodi&#225;lise e predizem um pior progn&#243;stico. Esta revis&#227;o aborda recentes evid&#234;ncias da utilidade do m&#233;todo na detec&#231;&#227;o da disfun&#231;&#227;o card&#237;aca cl&#237;nica e subcl&#237;nica, estratifica&#231;&#227;o do risco cardiovascular e avalia&#231;&#227;o das estrat&#233;gias de interven&#231;&#227;o terap&#234;utica.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Ecocardiografia Doppler</kwd>
        <kwd>Di&#225;lise Renal</kwd>
        <kwd>Avalia&#231;&#227;o de Risco</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>22</day>
        <month>09</month>
        <year>2010</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>ARTIGO DE REVIS&#195;O</bold>
    </p>
    <p>
      <bold>Altera&#231;&#245;es ecocardiogr&#225;ficas em pacientes com insufici&#234;ncia renal cr&#244;nica em programa de hemodi&#225;lise</bold>
    </p>
    <p>
      <bold>Silvio Henrique Barberato; Roberto Pecoits-Filho</bold>
    </p>
    <p>Pontif&#237;cia Universidade Cat&#243;lica do Paran&#225;, Curitiba, PR, Brasil</p>
    <p>
      <xref ref-type="corresp" rid="back">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p>Altera&#231;&#245;es de estrutura e fun&#231;&#227;o card&#237;acas detectadas pela ecocardiografia s&#227;o comuns em pacientes com doen&#231;a renal cr&#244;nica em hemodi&#225;lise e predizem um pior progn&#243;stico. Esta revis&#227;o aborda recentes evid&#234;ncias da utilidade do m&#233;todo na detec&#231;&#227;o da disfun&#231;&#227;o card&#237;aca cl&#237;nica e subcl&#237;nica, estratifica&#231;&#227;o do risco cardiovascular e avalia&#231;&#227;o das estrat&#233;gias de interven&#231;&#227;o terap&#234;utica.</p>
    <p><bold>Palavras-chave: </bold> Ecocardiografia Doppler, Di&#225;lise Renal, Avalia&#231;&#227;o de Risco.</p>
    <p>
      <bold>Doen&#231;a Renal Cr&#244;nica e Cardiopatia</bold>
    </p>
    <p>As complica&#231;&#245;es cardiovasculares s&#227;o a principal causa de &#243;bito dos pacientes portadores de doen&#231;a renal cr&#244;nica (DRC) em terapia de substitui&#231;&#227;o renal pela hemodi&#225;lise<sup>1,2</sup>. A mortalidade cardiovascular nesses indiv&#237;duos &#233; 10 a 20 vezes mais frequente que na popula&#231;&#227;o geral<sup>3</sup>. Embora mais de 50% dos indiv&#237;duos que iniciam o programa de hemodi&#225;lise apresentem alguma forma de doen&#231;a cardiovascular pr&#233;-existente<sup>4</sup>, os fatores de risco tradicionais para doen&#231;a cardiovascular n&#227;o explicam completamente esse excesso de risco, que parece ser influenciado pelos chamados fatores de risco n&#227;o tradicionais, peculiares da doen&#231;a renal cr&#244;nica<sup>1</sup>. O conjunto desses fatores acelera o curso da doen&#231;a arterial coronariana<sup>5</sup> e associa-se com uma maior preval&#234;ncia de hipertrofia ventricular, fibrose mioc&#225;rdica, valvopatias, arritmias e morte s&#250;bita<sup>6</sup>. A cardiomiopatia do paciente em hemodi&#225;lise deve-se principalmente &#224; presen&#231;a de cardiopatia isqu&#234;mica - por obstru&#231;&#227;o cr&#237;tica de coron&#225;rias, redu&#231;&#227;o de reserva coronariana ou altera&#231;&#245;es microvasculares - e altera&#231;&#245;es morfofuncionais do ventr&#237;culo esquerdo (VE) em resposta &#224; sobrecarga de press&#227;o e volume<sup>7</sup>. A fisiopatologia das transforma&#231;&#245;es induzidas pela uremia na c&#226;mara ventricular esquerda &#233; complexa e multifatorial.</p>
    <p>A sobrecarga de volume prov&#233;m da reten&#231;&#227;o hidrossalina, anemia e f&#237;stula arteriovenosa, levando &#224; hipertrofia exc&#234;ntrica do VE (aumento da massa secund&#225;rio ao aumento no comprimento do mi&#243;cito e no volume ventricular, com a espessura relativa de parede normal). A anemia, em particular, merece men&#231;&#227;o especial nesse grupo de pacientes. A associa&#231;&#227;o entre anemia, insufici&#234;ncia card&#237;aca congestiva e insufici&#234;ncia renal levou Silverberg e cols.<sup>8</sup> a propor o termo "s&#237;ndrome cardiorrenal"<sup>8</sup>. Afec&#231;&#245;es do cora&#231;&#227;o e rim podem ter etiologia comum, e a insufici&#234;ncia card&#237;aca pode levar &#224; uremia pr&#233;-renal; por sua vez, a diminui&#231;&#227;o da fun&#231;&#227;o renal pode gerar anemia, o que leva a maiores danos card&#237;acos. A corre&#231;&#227;o do hemat&#243;crito com o emprego da eritropoietina gerou benef&#237;cios cl&#237;nicos (melhora da classe funcional e redu&#231;&#227;o da necessidade de diur&#233;ticos) e morfofisiol&#243;gicos (melhora no remodelamento e na fun&#231;&#227;o ventricular esquerda)<sup>9</sup>.</p>
    <p>A sobrecarga de press&#227;o pode resultar da hipertens&#227;o arterial, arteriosclerose e, ocasionalmente, estenose a&#243;rtica, causando hipertrofia conc&#234;ntrica do VE (aumento da massa secund&#225;rio ao aumento da espessura do mi&#243;cito, sem modifica&#231;&#227;o significativa no volume ventricular e com a espessura relativa aumentada). Na aus&#234;ncia de interven&#231;&#245;es que reduzam a sobrecarga do VE, ocorre um comprometimento da adapta&#231;&#227;o da c&#226;mara com consequente aumento da morte celular e da fibrose mioc&#225;rdica, que levam &#224; diminui&#231;&#227;o da densidade capilar, disfun&#231;&#227;o diast&#243;lica, dist&#250;rbios da condu&#231;&#227;o intraventricular, dilata&#231;&#227;o e mais hipertrofia compensat&#243;ria<sup>10,11</sup>.</p>
    <p>Tais fen&#244;menos predisp&#245;em &#224; remodela&#231;&#227;o ventricular por ativa&#231;&#227;o neuro-humoral e ao aumento da excitabilidade el&#233;trica, elementos crescentemente relacionados &#224; maior incid&#234;ncia de morte s&#250;bita nesse grupo de pacientes<sup>6</sup>. Mesmo ap&#243;s o tratamento medicamentoso otimizado e os procedimentos de revasculariza&#231;&#227;o coronariana, uma parcela dos pacientes de hemodi&#225;lise sofre morte s&#250;bita, sugerindo que outros fatores, al&#233;m da isquemia mioc&#225;rdica, possam exercer um papel importante no desencadeamento de arritmias letais<sup>12</sup>.</p>
    <p>Potenciais substratos para a g&#234;nese de arritmias nesse cen&#225;rio cl&#237;nico incluem: altera&#231;&#245;es metab&#243;licas, disfun&#231;&#227;o sist&#243;lica e/ou diast&#243;lica, hipertrofia ventricular esquerda e sobrecarga de volume<sup>13</sup>. Em paralelo, ocorre o deslocamento da curva de press&#227;o-volume do VE para a esquerda, significando que pequenos incrementos de volume podem desencadear grandes eleva&#231;&#245;es da press&#227;o, com manifesta&#231;&#227;o cl&#237;nica de insufici&#234;ncia card&#237;aca congestiva<sup>2</sup>. A morte miocit&#225;ria induzida pela agress&#227;o conjunta da sobrecarga hemodin&#226;mica aliada aos fatores de risco pr&#243;prios da uremia, como anemia, hiperparatireoidismo, desnutri&#231;&#227;o, estresse oxidativo e inflama&#231;&#227;o cr&#244;nica, entre outros outros, torna o progn&#243;stico ainda mais sombrio.</p>
    <p>Embora o diagn&#243;stico cl&#237;nico da insufici&#234;ncia card&#237;aca possa ser feito com relativa seguran&#231;a, a interpreta&#231;&#227;o dos sinais cl&#237;nicos &#233; um problema na pr&#225;tica di&#225;ria. Sabe-se que a insufici&#234;ncia card&#237;aca clinicamente manifesta representa um preditor independente de mortalidade nos pacientes iniciando a terapia hemodial&#237;tica<sup>14</sup>, mas o discernimento da causa subjacente pode ser importante para direcionar a conduta terap&#234;utica. Algumas quest&#245;es, portanto, se tornam relevantes no manejo dessa popula&#231;&#227;o de alto risco: h&#225; uma simples sobrecarga de volume ou uma doen&#231;a card&#237;aca prim&#225;ria? Havendo cardiopatia, as fun&#231;&#245;es sist&#243;lica e/ou diast&#243;lica est&#227;o comprometidas? Podemos estimar press&#245;es de enchimento do VE?</p>
    <p>Nesse contexto, a utiliza&#231;&#227;o de m&#233;todos de investiga&#231;&#227;o complementar tecnicamente simples, de baixo custo relativo e com boa reprodutibilidade traz uma importante contribui&#231;&#227;o na evolu&#231;&#227;o do conhecimento da fisiopatologia da doen&#231;a e na avalia&#231;&#227;o de potenciais estrat&#233;gias de tratamento.</p>
    <p>
      <bold>Papel da ecocardiografia</bold>
    </p>
    <p>O diagn&#243;stico ecodopplercardiogr&#225;fico das anormalidades do VE &#233; um importante passo para a caracteriza&#231;&#227;o de indiv&#237;duos com maior risco cardiovascular, estimando a preval&#234;ncia da doen&#231;a card&#237;aca prim&#225;ria em uma popula&#231;&#227;o para estudar seus fatores predisponentes, o impacto progn&#243;stico e o efeito de interven&#231;&#245;es terap&#234;uticas<sup>15</sup>. O ecodopplercardiograma &#233; um exame complementar, n&#227;o invasivo, amplamente utilizado na avalia&#231;&#227;o da estrutura e fun&#231;&#227;o card&#237;acas, unindo v&#225;rias t&#233;cnicas de ultrassom em um s&#243; exame. Tradicionalmente, o modo M e o bidimensional permitem avaliar a massa e os volumes ventriculares, obtendo-se excelente acur&#225;cia para o diagn&#243;stico da hipertrofia, defini&#231;&#227;o do seu padr&#227;o geom&#233;trico (conc&#234;ntrica ou exc&#234;ntrica) e estimativa da fun&#231;&#227;o sist&#243;lica (de forma qualitativa ou quantitativa).</p>
    <p>Al&#233;m disso, as t&#233;cnicas derivadas do Doppler podem gerar informa&#231;&#245;es indiretas a respeito do relaxamento ventricular e de sua din&#226;mica de enchimento, que constituem a fisiologia da di&#225;stole. Em um estudo canadense que acompanhou 432 pacientes iniciando hemodi&#225;lise, somente 16% tinham ecodopplercardiograma normal<sup>16</sup>. O achado das altera&#231;&#245;es ecocardiogr&#225;ficas - como hipertrofia, dilata&#231;&#227;o e disfun&#231;&#227;o sist&#243;lica -, triplica o risco de insufici&#234;ncia card&#237;aca, independente de idade, diabetes e insufici&#234;ncia coronariana<sup>16</sup>.</p>
    <p>
      <bold>Hipertrofia ventricular esquerda</bold>
    </p>
    <p>A hipertrofia ventricular esquerda (HVE) &#233; altamente prevalente na DRC e associa-se a um progn&#243;stico francamente desfavor&#225;vel. Mais de dois ter&#231;os dos pacientes em di&#225;lise com HVE morrem de insufici&#234;ncia card&#237;aca congestiva ou morte s&#250;bita<sup>17</sup>, raz&#227;o pela qual &#233; um dos principais alvos de interven&#231;&#227;o terap&#234;utica, em conjunto com a doen&#231;a arterial coronariana. A incid&#234;ncia de HVE aumenta com o progressivo decl&#237;nio da fun&#231;&#227;o renal, havendo correla&#231;&#227;o linear inversa entre a massa ventricular esquerda e a taxa de filtra&#231;&#227;o glomerular<sup>18</sup>. Assim, a preval&#234;ncia de HVE oscila de 16% a 31% em indiv&#237;duos com DRC e filtra&#231;&#227;o glomerular &gt; 30 ml/min; de 38% a 45% naqueles com fun&#231;&#227;o renal mais comprometida<sup>18,19</sup>; de 60% a 75% naqueles iniciando terapia de substitui&#231;&#227;o renal; atingindo 70% a 90% em pacientes sob tratamento dial&#237;tico regular<sup>14,20,21</sup>.</p>
    <p>A massa do VE &#233; proporcional ao tamanho corporal e, tradicionalmente, a indexa&#231;&#227;o pela superf&#237;cie corp&#243;rea foi utilizada para essa corre&#231;&#227;o nos estudos cl&#225;ssicos. Diferentes valores de parti&#231;&#227;o foram empregados em diversos estudos prospectivos para a defini&#231;&#227;o da presen&#231;a de HVE. Como exemplos, Silberberg e cols.<sup>22</sup> usaram como valor de refer&#234;ncia 125 g/m<sup>2</sup>, enquanto Parfrey e cols.<sup>16</sup> usaram os valores empregados no estudo de Framingham (132 g/m<sup>2</sup> para homens e 100 g/m<sup>2</sup> para mulheres). Apesar dessa varia&#231;&#227;o, todos tiveram resultados semelhantes, demonstrando o claro efeito da massa ventricular aumentada no progn&#243;stico adverso<sup>16,22,23</sup>. Todavia, o indiv&#237;duo em hemodi&#225;lise est&#225; sujeito a grandes varia&#231;&#245;es do peso corporal, seja pelas altera&#231;&#245;es da volemia seja pelo comprometimento do estado nutricional, o que pode levar a erros de avalia&#231;&#227;o baseados na indexa&#231;&#227;o pela superf&#237;cie corp&#243;rea.</p>
    <p>Assim, a indexa&#231;&#227;o pela altura elevada &#224; pot&#234;ncia de 2,7, proposta por de Simone e cols.<sup>24</sup>, parece ser a mais acurada para a estimativa da massa do VE nesse grupo de pacientes. Aplicando esse conceito em pacientes de hemodi&#225;lise, demonstrou-se que o m&#233;todo baseado na altura tem valor ligeiramente superior para a predi&#231;&#227;o da mortalidade geral e cardiovascular do que aquele baseado na superf&#237;cie corp&#243;rea<sup>25</sup>. &#201; importante reconhecer que parte das altera&#231;&#245;es na geometria do VE em pacientes ur&#234;micos pode estar relacionada ao momento em que se faz o ecocardiograma. Logo ap&#243;s a sess&#227;o de di&#225;lise, &#233; comum haver a redu&#231;&#227;o do di&#226;metro diast&#243;lico do VE e o aumento da espessura da parede como conseq&#252;&#234;ncias da deple&#231;&#227;o de volume pela ultrafiltra&#231;&#227;o.</p>
    <p>Da mesma forma, o exame realizado logo antes de se iniciar a sess&#227;o pode diagnosticar dilata&#231;&#227;o do VE com hipertrofia exc&#234;ntrica, a qual ser&#225; "convertida" em conc&#234;ntrica ao final da sess&#227;o. Tais flutua&#231;&#245;es podem levar a erros de avalia&#231;&#227;o, que podem ser minimizados realizando-se o exame em um dia interdial&#237;tico (ter&#231;a ou quinta-feira), com hor&#225;rio entre as 12 e as 18 horas preferencialmente<sup>16</sup>.</p>
    <p>Apesar da HVE diagnosticada por ecocardiograma ser um preditor independente de mortalidade universalmente reconhecido, &#233; importante ressaltar que esse &#244;nus &#233; alcan&#231;ado ap&#243;s um per&#237;odo de pelo menos dois anos sob terapia dial&#237;tica<sup>14</sup>. A estratifica&#231;&#227;o adicional pode ser obtida por meio da categoriza&#231;&#227;o do padr&#227;o geom&#233;trico da hipertrofia mioc&#225;rdica, ou seja, se conc&#234;ntrica ou exc&#234;ntrica<sup>23</sup>. Um estudo prospectivo multic&#234;ntrico de 432 pacientes iniciando hemodi&#225;lise mostrou um tempo mediano de sobrevida de 48 meses para portadores de HVE conc&#234;ntrica e de 56 meses para a exc&#234;ntrica<sup>14,23</sup>.</p>
    <p>A monitoriza&#231;&#227;o da massa por meio de ecocardiograma seriado &#233; uma ferramenta cl&#237;nica adicional de grande import&#226;ncia para a avalia&#231;&#227;o do progn&#243;stico e do sucesso de interven&#231;&#245;es visando &#224; regress&#227;o da HVE<sup>26</sup>. Evid&#234;ncias indicam que a progress&#227;o da HVE em indiv&#237;duos com DRC &#233; preditiva de eventos cardiovasculares, independentemente dos valores basais da massa ventricular esquerda<sup>27</sup>. Por outro lado, a regress&#227;o da hipertrofia mioc&#225;rdica pode ser obtida com tratamento farmacol&#243;gico vigoroso, em especial com inibidores da enzima conversora da angiotensina-II, resultando em uma redu&#231;&#227;o do n&#250;mero de eventos cardiovasculares e em uma maior sobrevida<sup>21</sup>. Outras estrat&#233;gias de regress&#227;o da HVE na DRC terminal, como o tratamento com eritropoietina, controle restrito da volemia por ultrafiltra&#231;&#227;o agressiva e transplante renal, podem tamb&#233;m ter seus efeitos monitorados pela ecocardiografia.</p>
    <p>
      <bold>Disfun&#231;&#227;o sist&#243;lica do ventr&#237;culo esquerdo</bold>
    </p>
    <p>Em estudos utilizando diferentes metodologias, a preval&#234;ncia da disfun&#231;&#227;o sist&#243;lica do VE variou de 15% a 18% em pacientes de hemodi&#225;lise (iniciando o tratamento<sup>28</sup> ou em terapia cr&#244;nica regular<sup>29</sup>, respectivamente), chegando at&#233; 28% em indiv&#237;duos avaliados no momento do transplante renal<sup>20</sup>. A disfun&#231;&#227;o sist&#243;lica do VE &#233; um poderoso indicador de progn&#243;stico desfavor&#225;vel para indiv&#237;duos em programa de hemodi&#225;lise<sup>23</sup>, assim como ap&#243;s o transplante renal<sup>20</sup>. Os mecanismos respons&#225;veis s&#227;o multifatoriais, incluindo insufici&#234;ncia coronariana, anemia, hiperparatireoidismo, toxinas ur&#234;micas, m&#225; nutri&#231;&#227;o e sobrecarga hemodin&#226;mica prolongada<sup>30</sup>. A an&#225;lise da fun&#231;&#227;o sist&#243;lica do VE pelo ecocardiograma &#233; realizada usualmente por m&#233;todos que avaliam a fase de eje&#231;&#227;o, especialmente o encurtamento porcentual e a fra&#231;&#227;o de eje&#231;&#227;o. Essas t&#233;cnicas, baseadas em medidas feitas no endoc&#225;rdio, podem superestimar a contratilidade em pacientes com HVE.</p>
    <p>Alternativamente, um m&#233;todo baseado na medida da fra&#231;&#227;o de encurtamento da parede mioc&#225;rdica (<italic>midwall fractional shortening</italic>), proposto como medida da fun&#231;&#227;o sist&#243;lica independente da geometria do VE<sup>31</sup>, pode ser empregado nesse contexto, diagnosticando um menor desempenho sist&#243;lico em indiv&#237;duos com fra&#231;&#227;o de eje&#231;&#227;o normal. A despeito de tais pondera&#231;&#245;es, a disfun&#231;&#227;o sist&#243;lica do VE, diagnosticada por qualquer um dos m&#233;todos supracitados, associou-se de modo independente com eventos cardiovasculares fatais e n&#227;o fatais, n&#227;o se demonstrando diferen&#231;a no poder preditivo entre eles<sup>32</sup>.</p>
    <p>&#201; interessante salientar que, embora o efeito adverso da disfun&#231;&#227;o sist&#243;lica seja independente da massa ventricular esquerda, essas altera&#231;&#245;es interagem na predi&#231;&#227;o de desfechos cardiovasculares, atingindo-se risco m&#225;ximo nos pacientes com associa&#231;&#227;o de ambas<sup>32</sup>.</p>
    <p>
      <bold>Disfun&#231;&#227;o diast&#243;lica do ventr&#237;culo esquerdo</bold>
    </p>
    <p>A disfun&#231;&#227;o diast&#243;lica caracteriza-se por altera&#231;&#245;es do relaxamento e complac&#234;ncia ventricular, frequentemente cursando com aumento compensat&#243;rio das press&#245;es de enchimento em fases mais avan&#231;adas. Do ponto de vista hemodin&#226;mico, a eleva&#231;&#227;o da press&#227;o diast&#243;lica intraventricular esquerda &#233; o fen&#244;meno respons&#225;vel pela manifesta&#231;&#227;o da insufici&#234;ncia card&#237;aca, qualquer que seja a causa subjacente<sup>33</sup>.</p>
    <p>Estudos de necropsia e uremia experimental apontaram a presen&#231;a de fibrose intermiocardioc&#237;tica difusa espec&#237;fica no cora&#231;&#227;o de indiv&#237;duos ur&#234;micos, n&#227;o observada em hipertensos n&#227;o nefropatas, o que poderia implicar em instabilidade el&#233;trica (predispondo &#224; morte s&#250;bita) e altera&#231;&#227;o das propriedades diast&#243;licas do mioc&#225;rdio (predispondo &#224; eleva&#231;&#227;o das press&#245;es de enchimento)<sup>10,34</sup>.</p>
    <p>Entre os mecanismos fisiopatol&#243;gicos relacionados &#224; fibrose mioc&#225;rdica proeminente, postula-se a ativa&#231;&#227;o de fatores humorais associados &#224; hipertrofia - elevados n&#237;veis de angiotensina II, horm&#244;nio paratireoidiano, endotelina, aldosterona e catecolaminas plasm&#225;ticas - e &#224; presen&#231;a de isquemia mioc&#225;rdica subjacente<sup>13,34</sup>. O aumento da rigidez e a diminui&#231;&#227;o do relaxamento (secund&#225;rios &#224; fibrose) levam &#224; exacerba&#231;&#227;o dos efeitos das varia&#231;&#245;es vol&#234;micas sobre o enchimento do VE.</p>
    <p>Assim, mesmo em pacientes com fra&#231;&#227;o de eje&#231;&#227;o normal, um pequeno aumento no volume ventricular esquerdo pode gerar congest&#227;o pulmonar, enquanto a deple&#231;&#227;o vol&#234;mica pode induzir a diminui&#231;&#227;o no enchimento da c&#226;mara, ocasionando hipotens&#227;o arterial e instabilidade hemodin&#226;mica<sup>2</sup>. Configura-se, ent&#227;o, a import&#226;ncia de se estimar adequadamente n&#227;o somente a fun&#231;&#227;o sist&#243;lica do VE, mas tamb&#233;m a fun&#231;&#227;o diast&#243;lica, cujas altera&#231;&#245;es podem desencadear epis&#243;dios de edema agudo de pulm&#227;o e hipotens&#227;o intradial&#237;tica<sup>2,35</sup>.</p>
    <p>Estudos com casu&#237;sticas reduzidas reportaram uma preval&#234;ncia de disfun&#231;&#227;o diast&#243;lica do VE em pacientes ur&#234;micos variando de 50% a 65%, incluindo popula&#231;&#245;es pr&#233;-di&#225;lise, em di&#225;lise e p&#243;s-transplante<sup>17</sup>. Embora as altera&#231;&#245;es do enchimento ventricular esquerdo sejam frequentemente detectadas nos pacientes em hemodi&#225;lise, a preval&#234;ncia da disfun&#231;&#227;o diast&#243;lica e seu significado progn&#243;stico n&#227;o s&#227;o totalmente conhecidos nesse grupo<sup>13,36</sup>. As limita&#231;&#245;es da utiliza&#231;&#227;o de par&#226;metros ecodopplercardiogr&#225;ficos derivados do fluxo transvalvar mitral em estudos pr&#233;vios<sup>14,37</sup> devem-se ao fato de que estes &#237;ndices s&#227;o altamente dependentes das condi&#231;&#245;es de pr&#233;-carga<sup>38-40</sup>. Tal abordagem pode produzir resultados falso-negativos em pacientes hemodial&#237;ticos, diagnosticando como normais portadores de pseudonormaliza&#231;&#227;o do fluxo mitral (altas press&#245;es de enchimento mascarando a altera&#231;&#227;o de relaxamento do ventr&#237;culo esquerdo).</p>
    <p>Nesse contexto, os novos &#237;ndices ecodopplercardiogr&#225;ficos empregados na avalia&#231;&#227;o da fun&#231;&#227;o card&#237;aca representam um avan&#231;o importante no diagn&#243;stico. Nos &#250;ltimos anos, o Doppler tecidual (DT) do anel mitral foi introduzido no cen&#225;rio cl&#237;nico como um importante m&#233;todo de avalia&#231;&#227;o da fun&#231;&#227;o diast&#243;lica segmentar e global do VE. A velocidade diast&#243;lica precoce do anel mitral (E') correlaciona-se bem com &#237;ndices de relaxamento aferidos por investiga&#231;&#227;o invasiva<sup>41,42</sup>. Alguns pesquisadores demonstraram que as velocidades diast&#243;licas derivadas do Doppler tecidual do anel mitral (E' e A') s&#227;o "relativamente" independentes da pr&#233;-carga, n&#227;o tendo varia&#231;&#227;o significativa ap&#243;s uma sess&#227;o de hemodi&#225;lise, desde que respeitados certos limites "fisiol&#243;gicos" de redu&#231;&#227;o vol&#234;mica, ou seja, incapazes de desencadear altera&#231;&#245;es da frequ&#234;ncia card&#237;aca e press&#227;o arterial<sup>39,43</sup>. Por causa disso, E&#180; parece ser particularmente &#250;til em pacientes de hemodi&#225;lise, identificando a altera&#231;&#227;o do relaxamento independente das press&#245;es de enchimento do VE e, consequentemente, diferenciando a pseudonormaliza&#231;&#227;o do verdadeiro padr&#227;o normal de fun&#231;&#227;o diast&#243;lica<sup>39</sup>.</p>
    <p>Um recente estudo australiano acompanhou 129 pacientes com DRC terminal (sem evid&#234;ncia de isquemia do VE no ecocardiograma de estresse) por mais de dois anos, evidenciando que a velocidade diast&#243;lica tecidual adicionou um valor progn&#243;stico independente dos par&#226;metros cl&#237;nicos<sup>44</sup>. A raz&#227;o entre a velocidade diast&#243;lica precoce do fluxo mitral (E) e E' (conhecida como rela&#231;&#227;o E/E') foi o melhor preditor n&#227;o invasivo de eleva&#231;&#227;o das press&#245;es de enchimento na compara&#231;&#227;o entre m&#250;ltiplos &#237;ndices ecodopplercardiogr&#225;ficos e a press&#227;o diast&#243;lica final (medida por cateter de hemodin&#226;mica), seja usando E' septal<sup>45</sup> seja usando a m&#233;dia de E' septal e lateral<sup>46</sup>. Dessa forma, a rela&#231;&#227;o E/E' &#233; um &#237;ndice especialmente interessante para o diagn&#243;stico da disfun&#231;&#227;o diast&#243;lica avan&#231;ada. A possibilidade de indicar a eleva&#231;&#227;o da press&#227;o intraventricular por meio desse m&#233;todo permitiu, em paralelo, a demonstra&#231;&#227;o de seu importante valor progn&#243;stico em dois estudos recentes abordando pacientes com DRC terminal.</p>
    <p>Um estudo com 125 candidatos ao transplante renal demonstrou que a rela&#231;&#227;o E/E' &gt; 15 foi preditor independente do aumento da press&#227;o diast&#243;lica do VE (acima de 15 mmHg) e associou-se a uma maior mortalidade geral nesse grupo<sup>47</sup>. Outro estudo, abordando 220 indiv&#237;duos com DRC terminal acompanhados por quatro anos, concluiu que a rela&#231;&#227;o E/E' &gt; 15 foi preditor independente de mortalidade geral e cardiovascular, adicionando informa&#231;&#227;o progn&#243;stica acima e al&#233;m dos dados cl&#237;nicos, bioqu&#237;micos, massa ventricular e fun&#231;&#227;o sist&#243;lica<sup>48</sup>.</p>
    <p>
      <bold>Dilata&#231;&#227;o do &#225;trio esquerdo</bold>
    </p>
    <p>Fortes evid&#234;ncias apontam a dilata&#231;&#227;o do &#225;trio esquerdo (AE) como um robusto preditor de desfechos cardiovasculares na popula&#231;&#227;o geral e em diversos cen&#225;rios cl&#237;nicos<sup>49</sup>. Diretrizes recentes recomendam que a adequada quantifica&#231;&#227;o do tamanho do AE seja obtida pela estimativa do volume da c&#226;mara no modo bidimensional e n&#227;o pela tradicional medida do di&#226;metro anteroposterior do modo M<sup>50,51</sup>. Al&#233;m de ser superior na predi&#231;&#227;o de eventos cardiovasculares - incluindo fibrila&#231;&#227;o atrial, acidente vascular cerebral, insufici&#234;ncia card&#237;aca, infarto do mioc&#225;rdio e morte card&#237;aca<sup>52</sup> -, o volume do AE est&#225; relacionado &#224; gravidade e dura&#231;&#227;o da disfun&#231;&#227;o diast&#243;lica do VE<sup>53</sup>. Diferentemente dos &#237;ndices derivados do Doppler convencional (fluxo mitral) ou tecidual (anel mitral), os quais nos fornecem informa&#231;&#227;o moment&#226;nea e transit&#243;ria a respeito do enchimento ventricular esquerdo, o volume do AE funciona como um marcador cr&#244;nico da fun&#231;&#227;o diast&#243;lica, refletindo a m&#233;dia "hist&#243;rica" das press&#245;es de enchimento aumentadas<sup>53</sup>.</p>
    <p>Um estudo recente com pacientes de hemodi&#225;lise em ritmo sinusal e sem valvopatia mitral demonstrou que o volume do AE indexado para superf&#237;cie corp&#243;rea &gt;/ 35/ ml/m<sup>2</sup> foi o par&#226;metro mais acurado para detec&#231;&#227;o da pseudonormaliza&#231;&#227;o do fluxo mitral, em compara&#231;&#227;o com diversos &#237;ndices previamente testados<sup>54</sup>. Ampliando o valor cl&#237;nico do volume do AE, duas publica&#231;&#245;es recentes encontraram, utilizando m&#233;todos de indexa&#231;&#227;o diferentes (superf&#237;cie corp&#243;rea<sup>29</sup> ou altura elevada &#224; pot&#234;ncia 2,7<sup>55</sup>), que o &#237;ndice foi preditor independente da mortalidade em pacientes recebendo terapia renal substitutiva. O achado do volume do AE indexado &gt; 32 ml/m<sup>2</sup> forneceu informa&#231;&#227;o complementar aos dados cl&#237;nicos e ecocardiogr&#225;ficos tradicionais, incluindo fra&#231;&#227;o de eje&#231;&#227;o, rela&#231;&#227;o E/E' e massa ventricular esquerda<sup>29</sup>.</p>
    <p>Embora novos estudos observacionais e de interven&#231;&#227;o sejam necess&#225;rios para a valida&#231;&#227;o desses achados e defini&#231;&#227;o do melhor m&#233;todo de indexa&#231;&#227;o em nefropatas, &#233; recomend&#225;vel que a aferi&#231;&#227;o do volume de AE seja incorporada &#224; avalia&#231;&#227;o ecocardiogr&#225;fica de rotina desses pacientes, uma vez que o consenso da Sociedade Americana de Ecocardiografia j&#225; a preconiza na popula&#231;&#227;o geral<sup>51</sup>. Como a fun&#231;&#227;o diast&#243;lica do VE parece estar cronicamente comprometida na maioria dos pacientes de hemodi&#225;lise, mesmo naqueles que se apresentam assintom&#225;ticos<sup>13</sup>, o volume do AE pode oferecer a oportunidade de vislumbrar os indiv&#237;duos sob maior risco de manifestar insufici&#234;ncia card&#237;aca, arritmias atriais e m&#225; evolu&#231;&#227;o cl&#237;nica.</p>
    <p>
      <bold>Calcifica&#231;&#245;es valvares</bold>
    </p>
    <p>A calcifica&#231;&#227;o das valvas card&#237;acas &#233; frequente em pacientes cronicamente tratados com di&#225;lise. Alguns dados sugerem que a calcifica&#231;&#227;o valvar n&#227;o seja somente conseq&#252;&#234;ncia do envelhecimento natural e de dist&#250;rbios do metabolismo de c&#225;lcio-f&#243;sforo, mas tamb&#233;m decorra de inflama&#231;&#227;o, semelhante &#224; vista na aterosclerose<sup>56</sup>. Al&#233;m de poder repercutir clinicamente determinando refluxo e/ou estenose valvar, sua import&#226;ncia reside na associa&#231;&#227;o que se tem relatado entre a calcifica&#231;&#227;o valvar e um maior risco de mortalidade e eventos cardiovasculares no paciente ur&#234;mico.</p>
    <p>Um estudo realizado em 192 pacientes de di&#225;lise peritoneal encontrou calcifica&#231;&#227;o em pelo menos uma valva, mitral ou a&#243;rtica, em 32% da popula&#231;&#227;o<sup>57</sup>. Ap&#243;s acompanhamento m&#233;dio de 18 meses, a mortalidade cardiovascular foi de 22% contra 3% em indiv&#237;duos com e sem calcifica&#231;&#227;o valvar, respectivamente. Tal associa&#231;&#227;o foi independente das vari&#225;veis cl&#237;nicas e demogr&#225;ficas usuais, prote&#237;na C-reativa e doen&#231;a vascular ateroscler&#243;tica concomitante<sup>57</sup>.</p>
    <p>Outro interessante estudo prop&#244;s um escore de predi&#231;&#227;o do progn&#243;stico ap&#243;s transplante renal baseado no ecocardiograma. Ap&#243;s acompanhamento de 203 pacientes transplantados (idade m&#233;dia de 47 &#177; 12 anos, 93 % deles em di&#225;lise), os preditores independentes de mortalidade foram: idade <underline>&gt;</underline> 50 anos; dimens&#227;o sist&#243;lica do VE <underline>&gt;</underline> 35 mm; espessura de parede <underline>&gt;</underline> 14 mm; e presen&#231;a de calcifica&#231;&#227;o do anel mitral<sup>58</sup>. Pacientes com idade <underline>&gt;</underline> 50 anos e dois dos outros tr&#234;s preditores tiveram mortalidade de 82%<sup>58</sup>, em cinco anos. Em contraste com esses achados, um estudo feito com 202 de pacientes de hemodi&#225;lise (com preval&#234;ncia de 23% de calcifica&#231;&#227;o valvar) n&#227;o demonstrou valor progn&#243;stico independente ap&#243;s ajuste para fatores de risco e massa ventricular esquerda<sup>59</sup>.</p>
    <p>
      <bold>Doen&#231;a peric&#225;rdica</bold>
    </p>
    <p>A pericardite aguda pode ocorrer em aproximadamente 20% dos pacientes ur&#234;micos, antes do in&#237;cio da di&#225;lise ou na vig&#234;ncia de di&#225;lise cr&#244;nica<sup>60</sup>. Uremia e/ou di&#225;lise ineficiente s&#227;o as causas mais frequentes. Indiv&#237;duos sob hemodi&#225;lise de manuten&#231;&#227;o, com derrame peric&#225;rdico importante, usualmente n&#227;o respondem satisfatoriamente &#224; intensifica&#231;&#227;o da di&#225;lise e podem ser encaminhados para drenagem peric&#225;rdica eletiva precoce no intuito de evitar complica&#231;&#245;es hemodin&#226;micas<sup>61</sup>. J&#225; a pericardite constritiva ocorre menos frequentemente em pacientes de hemodi&#225;lise.</p>
    <p>
      <bold>Ecocardiografia sob estresse</bold>
    </p>
    <p>A utiliza&#231;&#227;o da ecocardiografia sob estresse farmacol&#243;gico nos portadores de DRC terminal &#233; uma estrat&#233;gia bastante atraente, uma vez que possibilita a pesquisa de isquemia mioc&#225;rdica sem exigir do paciente a capacidade de exercitar-se e fornece adicionalmente a estimativa da fun&#231;&#227;o sist&#243;lica basal do VE. Al&#233;m disso, a presen&#231;a e extens&#227;o da isquemia durante o exame t&#234;m valor progn&#243;stico independente para mortalidade geral nesse grupo de indiv&#237;duos<sup>62</sup>. Um maior volume de evid&#234;ncias foram geradas com o uso da dobutamina como agente estressor. O conjunto das informa&#231;&#245;es dispon&#237;veis n&#227;o aponta diferen&#231;as significativas de acur&#225;cia e valor preditivo negativo em compara&#231;&#227;o &#224; medicina nuclear, quando se pesquisa doen&#231;a coronariana obstrutiva em candidatos ao transplante renal (incluindo aqueles em di&#225;lise)<sup>63,64</sup>.</p>
    <p>Alternativamente, dois pequenos estudos sugeriram a utilidade do ecocardiograma sob estresse com dipiridamol no diagn&#243;stico da isquemia<sup>65</sup> e na predi&#231;&#227;o do progn&#243;stico<sup>66</sup>. Embora pacientes com DRC e ecocardiograma sob estresse normal tenham melhor progn&#243;stico que aqueles com estudo anormal, a taxa de mortalidade permanece substancial no primeiro grupo<sup>62</sup>, se compararmos com o excelente progn&#243;stico conferido pelo teste normal na popula&#231;&#227;o geral, o que pode ser explicado pelo perfil de alto risco peculiar ao indiv&#237;duo nefropata.</p>
    <p>Al&#233;m disso, um estudo nacional apontou que o exame possui uma limitada sensibilidade na vig&#234;ncia de doen&#231;a uniarterial coronariana e obstru&#231;&#245;es entre 50% e 70% da luz do vaso<sup>67</sup>. Assim, a abordagem individualizada deve ser ponderada em indiv&#237;duos com maior risco, pois a cinecoronariografia pode ser ainda de fundamental import&#226;ncia na detec&#231;&#227;o de doen&#231;a arterial coronariana clinicamente relevante<sup>64</sup>.</p>
    <p>
      <bold>Conclus&#227;o</bold>
    </p>
    <p>O corpo de evid&#234;ncias indica o extraordin&#225;rio papel da ecodopplercardiografia na melhoria da qualidade da avalia&#231;&#227;o cl&#237;nica global do paciente com DRC em di&#225;lise. A literatura e a pr&#225;tica cl&#237;nica atuais t&#234;m real&#231;ado a utilidade do m&#233;todo no diagn&#243;stico da disfun&#231;&#227;o card&#237;aca subcl&#237;nica, no refinamento do diagn&#243;stico cl&#237;nico de insufici&#234;ncia card&#237;aca, na predi&#231;&#227;o do risco cardiovascular e no direcionamento e acompanhamento das estrat&#233;gias de tratamento. Os desfechos ecodopplercardiogr&#225;ficos t&#234;m sido comprovados como marcadores substitutos &#250;teis para estudos de progn&#243;stico e interven&#231;&#227;o. Diretrizes norte-americanas recomendam o ecodopplercardiograma para todos os pacientes de di&#225;lise, um a tr&#234;s meses ap&#243;s o in&#237;cio da terapia renal substitutiva e em intervalos de tr&#234;s anos subseq&#252;entemente, a despeito dos sintomas<sup>68</sup>. Nossa opini&#227;o tamb&#233;m &#233; de que todo paciente iniciando a terapia dial&#237;tica deva ser submetido ao ecocardiograma.</p>
    <p>Entretanto, intervalos menores entre os exames podem ser de valor cl&#237;nico em condutas individualizadas. Est&#225; comprovado que o acompanhamento com ecocardiogramas seriados adiciona valor progn&#243;stico al&#233;m do exame basal, possibilitando a monitoriza&#231;&#227;o da regress&#227;o ou n&#227;o das altera&#231;&#245;es do VE<sup>26</sup>. Futuramente, novos m&#233;todos ecodopplercardiogr&#225;ficos com a propriedade de investigar doen&#231;a mioc&#225;rdica subcl&#237;nica - como <italic>strain, strain rate</italic> e caracteriza&#231;&#227;o ultrass&#244;nica tecidual -, poder&#227;o beneficiar ainda mais esse grupo de pacientes sob excessivo risco cardiovascular.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
    <p>
      <fn id="back" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p> Silvio Henrique Barberato </p>
        <p> Rua Saint Hilaire, 122/203, &#193;gua Verde </p>
        <p> 80.240-140, Curitiba, PR, Brasil </p>
        <p> E-mail: </p>
        <p><email xlink:href="msbarberato@terra.com.br">msbarberato@terra.com.br</email>, </p>
        <p>
          <email xlink:href="silviohb@cardiol.br">silviohb@cardiol.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 26/07/08, revisado recebido em 12/09/08; aceito em 13/10/08.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Sarnak MJ, Levey    AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as    a risk factor for development of cardiovascular disease: a statement from the    American Heart Association Councils on Kidney in Cardiovascular Disease, High    Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention.    Circulation. 2003; 108: 2154-69.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention</article-title>
          <source>Circulation</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>2154</fpage>
          <lpage>69</lpage>
          <volume>108</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sarnak</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Levey</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Schoolwerth</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Coresh</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Culleton</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Hamm</surname>
              <given-names>LL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. London GM. Cardiovascular    disease in chronic renal failure: pathophysiologic aspects. Semin Dial. 2003;    16: 85-94.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiovascular disease in chronic renal failure: pathophysiologic aspects</article-title>
          <source>Semin Dial</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>85</fpage>
          <lpage>94</lpage>
          <volume>16</volume>
          <person-group person-group-type="author">
            <name>
              <surname>London</surname>
              <given-names>GM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Foley RN, Parfrey    PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal    disease. Am J Kidney Dis. 1998; 32: S112-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Clinical epidemiology of cardiovascular disease in chronic renal disease</article-title>
          <source>Am J Kidney Dis</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>S112</fpage>
          <lpage>9</lpage>
          <volume>32</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Foley</surname>
              <given-names>RN</given-names>
            </name>
            <name>
              <surname>Parfrey</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Sarnak</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Foley RN, Herzog    CA, Collins AJ. Smoking and cardiovascular outcomes in dialysis patients: the    United States Renal Data System Wave 2 study. Kidney Int. 2003; 63: 1462-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Smoking and cardiovascular outcomes in dialysis patients: the United States Renal Data System Wave 2 study</article-title>
          <source>Kidney Int</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1462</fpage>
          <lpage>7</lpage>
          <volume>63</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Foley</surname>
              <given-names>RN</given-names>
            </name>
            <name>
              <surname>Herzog</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Collins</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Stenvinkel P,    Pecoits-Filho R, Lindholm B. Coronary artery disease in end-stage renal disease:    no longer a simple plumbing problem. J Am Soc Nephrol. 2003; 14: 1927-39.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem</article-title>
          <source>J Am Soc Nephrol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1927</fpage>
          <lpage>39</lpage>
          <volume>14</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Stenvinkel</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Pecoits-Filho</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Lindholm</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. McCullough PA.    Cardiovascular disease in chronic kidney disease from a cardiologist's perspective.    Curr Opin Nephrol Hypertens. 2004; 13: 591-600.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiovascular disease in chronic kidney disease from a cardiologist's perspective</article-title>
          <source>Curr Opin Nephrol Hypertens</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>591</fpage>
          <lpage>600</lpage>
          <volume>13</volume>
          <person-group person-group-type="author">
            <name>
              <surname>McCullough</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Parfrey PS,    Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure.    J Am Soc Nephrol. 1999; 10: 1606-15.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The clinical epidemiology of cardiac disease in chronic renal failure</article-title>
          <source>J Am Soc Nephrol</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>1606</fpage>
          <lpage>15</lpage>
          <volume>10</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Parfrey</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Foley</surname>
              <given-names>RN</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Silverberg DS,    Wexler D, Iaina A, Steinbruch S, Wollman Y, Schwartz D. Anemia, chronic renal    disease and congestive heart failurethe cardio renal anemia syndrome:    the need for cooperation between cardiologists and nephrologists. Int Urol Nephrol.    2006; 38: 295-310.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Anemia, chronic renal disease and congestive heart failure-the cardio renal anemia syndrome: the need for cooperation between cardiologists and nephrologists</article-title>
          <source>Int Urol Nephrol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>295</fpage>
          <lpage>310</lpage>
          <volume>38</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Silverberg</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Wexler</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Iaina</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Steinbruch</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wollman</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Schwartz</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Palazzuoli A,    Silverberg DS, Iovine F, Calabro A, Campagna MS, Gallotta M, et al. Effects    of beta-erythropoietin treatment on left ventricular remodeling, systolic function,    and B-type natriuretic peptide levels in patients with the cardiorenal anemia    syndrome. Am Heart J. 2007; 154: 645 e9-15.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects of beta-erythropoietin treatment on left ventricular remodeling, systolic function, and B-type natriuretic peptide levels in patients with the cardiorenal anemia syndrome</article-title>
          <source>Am Heart J</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>645 e9</fpage>
          <lpage>15</lpage>
          <volume>154</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Palazzuoli</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Silverberg</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Iovine</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Calabro</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Campagna</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Gallotta</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Ritz E, Rambausek    M, Mall G, Ruffmann K, Mandelbaum A. Cardiac changes in uraemia and their possible    relationship to cardiovascular instability on dialysis. Nephrol Dial Transplant.    1990; 5 (Suppl 1): 93-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiac changes in uraemia and their possible relationship to cardiovascular instability on dialysis</article-title>
          <source>Nephrol Dial Transplant</source>
          <date>
            <year>1990</year>
          </date>
          <fpage>93</fpage>
          <lpage>7</lpage>
          <volume>5</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ritz</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Rambausek</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mall</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ruffmann</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Mandelbaum</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Parfrey PS,    Harnett JD, Foley RN. Heart failure and ischemic heart disease in chronic uremia.    Curr Opin Nephrol Hypertens. 1995; 4: 105-10.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Heart failure and ischemic heart disease in chronic uremia</article-title>
          <source>Curr Opin Nephrol Hypertens</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>105</fpage>
          <lpage>10</lpage>
          <volume>4</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Parfrey</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Harnett</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Foley</surname>
              <given-names>RN</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Herzog CA.    Sudden cardiac death and acute myocardial infarction in dialysis patients: perspectives    of a cardiologist. Semin Nephrol. 2005; 25: 363-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Sudden cardiac death and acute myocardial infarction in dialysis patients: perspectives of a cardiologist</article-title>
          <source>Semin Nephrol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>363</fpage>
          <lpage>6</lpage>
          <volume>25</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Herzog</surname>
              <given-names>CA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. London GM.    Left ventricular alterations and end-stage renal disease. Nephrol Dial Transplant.    2002; 17 (Suppl 1): 29-36.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Left ventricular alterations and end-stage renal disease</article-title>
          <source>Nephrol Dial Transplant</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>29</fpage>
          <lpage>36</lpage>
          <volume>17</volume>
          <person-group person-group-type="author">
            <name>
              <surname>London</surname>
              <given-names>GM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Foley RN, Parfrey    PS, Harnett JD, Kent GM, Martin CJ, Murray DC, et al. Clinical and echocardiographic    disease in patients starting end-stage renal disease therapy. Kidney Int. 1995;    47: 186-92.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Clinical and echocardiographic disease in patients starting end-stage renal disease therapy</article-title>
          <source>Kidney Int</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>186</fpage>
          <lpage>92</lpage>
          <volume>47</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Foley</surname>
              <given-names>RN</given-names>
            </name>
            <name>
              <surname>Parfrey</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Harnett</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Kent</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Martin</surname>
              <given-names>CJ</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>DC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Yamada H, Goh    PP, Sun JP, Odabashian J, Garcia MJ, Thomas JD, et al. Prevalence of left ventricular    diastolic dysfunction by Doppler echocardiography: clinical application of the    Canadian consensus guidelines. J Am Soc Echocardiogr. 2002; 15: 1238-44.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prevalence of left ventricular diastolic dysfunction by Doppler echocardiography: clinical application of the Canadian consensus guidelines</article-title>
          <source>J Am Soc Echocardiogr</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1238</fpage>
          <lpage>44</lpage>
          <volume>15</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Yamada</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Goh</surname>
              <given-names>PP</given-names>
            </name>
            <name>
              <surname>Sun</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Odabashian</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Garcia</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Parfrey PS,    Foley RN, Harnett JD, Kent GM, Murray D, Barre PE. Outcome and risk factors    of ischemic heart disease in chronic uremia. Kidney Int. 1996; 49: 1428-34.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Outcome and risk factors of ischemic heart disease in chronic uremia</article-title>
          <source>Kidney Int</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>1428</fpage>
          <lpage>34</lpage>
          <volume>49</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Parfrey</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Foley</surname>
              <given-names>RN</given-names>
            </name>
            <name>
              <surname>Harnett</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Kent</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Barre</surname>
              <given-names>PE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Kunz K, Dimitrov    Y, Muller S, Chantrel F, Hannedouche T. Uraemic cardiomyopathy. Nephrol Dial    Transplant. 1998; 13 (Suppl 4): 39-43.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Uraemic cardiomyopathy</article-title>
          <source>Nephrol Dial Transplant</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>39</fpage>
          <lpage>43</lpage>
          <volume>13</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kunz</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Dimitrov</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Muller</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chantrel</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Hannedouche</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Levin A, Singer    J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the    predialysis population: identifying opportunities for intervention. Am J Kidney    Dis. 1996; 27: 347-54.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention</article-title>
          <source>Am J Kidney Dis</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>347</fpage>
          <lpage>54</lpage>
          <volume>27</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Levin</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Singer</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Thompson</surname>
              <given-names>CR</given-names>
            </name>
            <name>
              <surname>Ross</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Lewis</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Tucker B, Fabbian    F, Giles M, Thuraisingham RC, Raine AE, Baker LR. Left ventricular hypertrophy    and ambulatory blood pressure monitoring in chronic renal failure. Nephrol Dial    Transplant. 1997; 12: 724-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Left ventricular hypertrophy and ambulatory blood pressure monitoring in chronic renal failure</article-title>
          <source>Nephrol Dial Transplant</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>724</fpage>
          <lpage>8</lpage>
          <volume>12</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Tucker</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Fabbian</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Giles</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Thuraisingham</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Raine</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>LR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. McGregor E,    Jardine AG, Murray LS, Dargie HJ, Rodger RS, Junor BJ, et al. Preoperative echocardiographic    abnormalities and adverse outcome following renal transplantation. Nephrol Dial    Transplant. 1998; 13: 1499-505.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Preoperative echocardiographic abnormalities and adverse outcome following renal transplantation</article-title>
          <source>Nephrol Dial Transplant</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>1499</fpage>
          <lpage>505</lpage>
          <volume>13</volume>
          <person-group person-group-type="author">
            <name>
              <surname>McGregor</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Jardine</surname>
              <given-names>AG</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Dargie</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Rodger</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Junor</surname>
              <given-names>BJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. London GM,    Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, et al. Alterations of    left ventricular hypertrophy in and survival of patients receiving hemodialysis:    follow-up of an interventional study. J Am Soc Nephrol. 2001; 12: 2759-67.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study</article-title>
          <source>J Am Soc Nephrol</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>2759</fpage>
          <lpage>67</lpage>
          <volume>12</volume>
          <person-group person-group-type="author">
            <name>
              <surname>London</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Pannier</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Guerin</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Blacher</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Marchais</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Darne</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Silberberg    JS, Barre PE, Prichard SS, Sniderman AD. Impact of left ventricular hypertrophy    on survival in end-stage renal disease. Kidney Int. 1989; 36: 286-90.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Impact of left ventricular hypertrophy on survival in end-stage renal disease</article-title>
          <source>Kidney Int</source>
          <date>
            <year>1989</year>
          </date>
          <fpage>286</fpage>
          <lpage>90</lpage>
          <volume>36</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Silberberg</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Barre</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>Prichard</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Sniderman</surname>
              <given-names>AD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Foley RN, Parfrey    PS, Harnett JD, Kent GM, Murray DC, Barre PE. The prognostic importance of left    ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol. 1995; 5: 2024-31.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The prognostic importance of left ventricular geometry in uremic cardiomyopathy</article-title>
          <source>J Am Soc Nephrol</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>2024</fpage>
          <lpage>31</lpage>
          <volume>5</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Foley</surname>
              <given-names>RN</given-names>
            </name>
            <name>
              <surname>Parfrey</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Harnett</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Kent</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Barre</surname>
              <given-names>PE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. de Simone G,    Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, et al. Left ventricular    mass and body size in normotensive children and adults: assessment of allometric    relations and impact of overweight. J Am Coll Cardiol. 1992; 20: 1251-60.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1992</year>
          </date>
          <fpage>1251</fpage>
          <lpage>60</lpage>
          <volume>20</volume>
          <person-group person-group-type="author">
            <name>
              <surname>de Simone</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Daniels</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Devereux</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Meyer</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Roman</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>de Divitiis</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Zoccali C,    Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Cataliotti A, et al. Prognostic    impact of the indexation of left ventricular mass in patients undergoing dialysis.    J Am Soc Nephrol. 2001; 12: 2768-74.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis</article-title>
          <source>J Am Soc Nephrol</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>2768</fpage>
          <lpage>74</lpage>
          <volume>12</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Zoccali</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Benedetto</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Mallamaci</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Tripepi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Giacone</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cataliotti</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26. Foley RN, Parfrey    PS, Kent GM, Harnett JD, Murray DC, Barre PE. Serial change in echocardiographic    parameters and cardiac failure in end-stage renal disease. J Am Soc Nephrol.    2000; 11: 912-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Serial change in echocardiographic parameters and cardiac failure in end-stage renal disease</article-title>
          <source>J Am Soc Nephrol</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>912</fpage>
          <lpage>6</lpage>
          <volume>11</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Foley</surname>
              <given-names>RN</given-names>
            </name>
            <name>
              <surname>Parfrey</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Kent</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Harnett</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Barre</surname>
              <given-names>PE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. Zoccali C,    Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Stancanelli B, et al. Left    ventricular mass monitoring in the follow-up of dialysis patients: prognostic    value of left ventricular hypertrophy progression. Kidney Int. 2004; 65: 1492-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Left ventricular mass monitoring in the follow-up of dialysis patients: prognostic value of left ventricular hypertrophy progression</article-title>
          <source>Kidney Int</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>1492</fpage>
          <lpage>8</lpage>
          <volume>65</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Zoccali</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Benedetto</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Mallamaci</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Tripepi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Giacone</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Stancanelli</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28. Parfrey PS,    Foley RN, Harnett JD, Kent GM, Murray DC, Barre PE. Outcome and risk factors    for left ventricular disorders in chronic uraemia. Nephrol Dial Transplant.    1996; 11: 1277-85.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Outcome and risk factors for left ventricular disorders in chronic uraemia</article-title>
          <source>Nephrol Dial Transplant</source>
          <date>
            <year>1996</year>
          </date>
          <fpage>1277</fpage>
          <lpage>85</lpage>
          <volume>11</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Parfrey</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Foley</surname>
              <given-names>RN</given-names>
            </name>
            <name>
              <surname>Harnett</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Kent</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Murray</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Barre</surname>
              <given-names>PE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B29">
        <mixed-citation>29. Barberato SH,    Pecoits Filho R. Prognostic value of left atrial volume index in hemodialysis    patients. Arq Bras Cardiol. 2007; 88: 643-50.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic value of left atrial volume index in hemodialysis patients</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>643</fpage>
          <lpage>50</lpage>
          <volume>88</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Barberato</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Pecoits Filho</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B30">
        <mixed-citation>30. Dyadyk OI,    Bagriy AE, Yarovaya NF. Disorders of left ventricular structure and function    in chronic uremia: how often, why and what to do with it? Eur J Heart Fail.    1999; 1: 327-36.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Disorders of left ventricular structure and function in chronic uremia: how often, why and what to do with it?</article-title>
          <source>Eur J Heart Fail</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>327</fpage>
          <lpage>36</lpage>
          <volume>1</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Dyadyk</surname>
              <given-names>OI</given-names>
            </name>
            <name>
              <surname>Bagriy</surname>
              <given-names>AE</given-names>
            </name>
            <name>
              <surname>Yarovaya</surname>
              <given-names>NF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B31">
        <mixed-citation>31. Shimizu G,    Hirota Y, Kita Y, Kawamura K, Saito T, Gaasch WH. Left ventricular midwall mechanics    in systemic arterial hypertension: myocardial function is depressed in pressure-overload    hypertrophy. Circulation. 1991; 83: 1676-84.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Left ventricular midwall mechanics in systemic arterial hypertension: myocardial function is depressed in pressure-overload hypertrophy</article-title>
          <source>Circulation</source>
          <date>
            <year>1991</year>
          </date>
          <fpage>1676</fpage>
          <lpage>84</lpage>
          <volume>83</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Shimizu</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Hirota</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kita</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kawamura</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Saito</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gaasch</surname>
              <given-names>WH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B32">
        <mixed-citation>32. Zoccali C,    Benedetto FA, Mallamaci F, Tripepi G, Giacone G, Cataliotti A, et al. Prognostic    value of echocardiographic indicators of left ventricular systolic function    in asymptomatic dialysis patients. J Am Soc Nephrol. 2004;15:1029-37.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic value of echocardiographic indicators of left ventricular systolic function in asymptomatic dialysis patients</article-title>
          <source>J Am Soc Nephrol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>1029</fpage>
          <lpage>37</lpage>
          <volume>15</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Zoccali</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Benedetto</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Mallamaci</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Tripepi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Giacone</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Cataliotti</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B33">
        <mixed-citation>33. Oh JK. Echocardiography    as a noninvasive Swan-Ganz catheter. Circulation. 2005; 111: 3192-4.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Echocardiography as a noninvasive Swan-Ganz catheter</article-title>
          <source>Circulation</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>3192</fpage>
          <lpage>4</lpage>
          <volume>111</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Oh</surname>
              <given-names>JK</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B34">
        <mixed-citation>34. Mall G, Huther    W, Schneider J, Lundin P, Ritz E. Diffuse intermyocardiocytic fibrosis in uraemic    patients. Nephrol Dial Transplant. 1990; 5: 39-44.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Diffuse intermyocardiocytic fibrosis in uraemic patients</article-title>
          <source>Nephrol Dial Transplant</source>
          <date>
            <year>1990</year>
          </date>
          <fpage>39</fpage>
          <lpage>44</lpage>
          <volume>5</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mall</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Huther</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Schneider</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lundin</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ritz</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B35">
        <mixed-citation>35. de Simone G.    Left ventricular geometry and hypotension in end-stage renal disease: a mechanical    perspective. J Am Soc Nephrol. 2003; 14: 2421-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Left ventricular geometry and hypotension in end-stage renal disease: a mechanical perspective</article-title>
          <source>J Am Soc Nephrol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>2421</fpage>
          <lpage>7</lpage>
          <volume>14</volume>
          <person-group person-group-type="author">
            <name>
              <surname>de Simone</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B36">
        <mixed-citation>36. Alpert MA.    Cardiac performance and morphology in end-stage renal disease. Am J Med Sci.    2003; 325: 168-78.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiac performance and morphology in end-stage renal disease</article-title>
          <source>Am J Med Sci</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>168</fpage>
          <lpage>78</lpage>
          <volume>325</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Alpert</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B37">
        <mixed-citation>37. Gupta S, Dev    V, Kumar MV, Dash SC. Left ventricular diastolic function in end-stage renal    disease and the impact of hemodialysis. Am J Cardiol. 1993; 71: 1427-30.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Left ventricular diastolic function in end-stage renal disease and the impact of hemodialysis</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>1427</fpage>
          <lpage>30</lpage>
          <volume>71</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gupta</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dev</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Kumar</surname>
              <given-names>MV</given-names>
            </name>
            <name>
              <surname>Dash</surname>
              <given-names>SC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B38">
        <mixed-citation>38. Chakko S, Girgis    I, Contreras G, Perez G, Kessler KM, Myerburg RJ. Effects of hemodialysis on    left ventricular diastolic filling. Am J Cardiol. 1997; 79: 106-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effects of hemodialysis on left ventricular diastolic filling</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>106</fpage>
          <lpage>8</lpage>
          <volume>79</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Chakko</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Girgis</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Contreras</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Perez</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kessler</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Myerburg</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B39">
        <mixed-citation>39. Barberato SH,    Mantilla DE, Misocami MA, Goncalves SM, Bignelli AT, Riella MC, et al. Effect    of preload reduction by hemodialysis on left atrial volume and echocardiographic    Doppler parameters in patients with end-stage renal disease. Am J Cardiol. 2004;    94: 1208-10.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effect of preload reduction by hemodialysis on left atrial volume and echocardiographic Doppler parameters in patients with end-stage renal disease</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>1208</fpage>
          <lpage>10</lpage>
          <volume>94</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Barberato</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Mantilla</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Misocami</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Goncalves</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Bignelli</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Riella</surname>
              <given-names>MC</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B40">
        <mixed-citation>40. Barberato SH,    Pecoits Filho R. Influence of preload reduction on Tei index and other Doppler    echocardiographic parameters of left ventricular function. Arq Bras Cardiol.    2006; 86: 425-31.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Influence of preload reduction on Tei index and other Doppler echocardiographic parameters of left ventricular function</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>425</fpage>
          <lpage>31</lpage>
          <volume>86</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Barberato</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Pecoits Filho</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B41">
        <mixed-citation>41. Nagueh SF,    Middleton KJ, Kopelen HA, Zoghbi WA, Quinones MA. Doppler tissue imaging: a    noninvasive technique for evaluation of left ventricular relaxation and estimation    of filling pressures. J Am Coll Cardiol. 1997; 30: 1527-33.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>1527</fpage>
          <lpage>33</lpage>
          <volume>30</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Nagueh</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Middleton</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Kopelen</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Zoghbi</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Quinones</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B42">
        <mixed-citation>42. Sohn DW, Chai    IH, Lee DJ, Kim HC, Kim HS, Oh BH, et al. Assessment of mitral annulus velocity    by Doppler tissue imaging in the evaluation of left ventricular diastolic function.    J Am Coll Cardiol. 1997; 30: 474-80.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1997</year>
          </date>
          <fpage>474</fpage>
          <lpage>80</lpage>
          <volume>30</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sohn</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Chai</surname>
              <given-names>IH</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Oh</surname>
              <given-names>BH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B43">
        <mixed-citation>43. Graham RJ,    Gelman JS, Donelan L, Mottram PM, Peverill RE. Effect of preload reduction by    haemodialysis on new indices of diastolic function. Clin Sci (Lond). 2003; 105:    499-506.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Effect of preload reduction by haemodialysis on new indices of diastolic function</article-title>
          <source>Clin Sci (Lond)</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>499</fpage>
          <lpage>506</lpage>
          <volume>105</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Graham</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Gelman</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Donelan</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Mottram</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Peverill</surname>
              <given-names>RE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B44">
        <mixed-citation>44. Rakhit DJ,    Zhang XH, Leano R, Armstrong KA, Isbel NM, Marwick TH. Prognostic role of subclinical    left ventricular abnormalities and impact of transplantation in chronic kidney    disease. Am Heart J. 2007; 153: 656-64.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic role of subclinical left ventricular abnormalities and impact of transplantation in chronic kidney disease</article-title>
          <source>Am Heart J</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>656</fpage>
          <lpage>64</lpage>
          <volume>153</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rakhit</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>XH</given-names>
            </name>
            <name>
              <surname>Leano</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Armstrong</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Isbel</surname>
              <given-names>NM</given-names>
            </name>
            <name>
              <surname>Marwick</surname>
              <given-names>TH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B45">
        <mixed-citation>45. Ommen SR, Nishimura    RA, Appleton CP, Miller FA, Oh JK, Redfield MM, et al. Clinical utility of Doppler    echocardiography and tissue Doppler imaging in the estimation of left ventricular    filling pressures: a comparative simultaneous Doppler-catheterization study.    Circulation. 2000; 102: 1788-94.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation of left ventricular filling pressures: a comparative simultaneous Doppler-catheterization study</article-title>
          <source>Circulation</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>1788</fpage>
          <lpage>94</lpage>
          <volume>102</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ommen</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Nishimura</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Appleton</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Oh</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Redfield</surname>
              <given-names>MM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B46">
        <mixed-citation>46. Dokainish H,    Zoghbi WA, Lakkis NM, Al-Bakshy F, Dhir M, Quinones MA, et al. Optimal noninvasive    assessment of left ventricular filling pressures: a comparison of tissue Doppler    echocardiography and B-type natriuretic peptide in patients with pulmonary artery    catheters. Circulation. 2004; 109: 2432-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Optimal noninvasive assessment of left ventricular filling pressures: a comparison of tissue Doppler echocardiography and B-type natriuretic peptide in patients with pulmonary artery catheters</article-title>
          <source>Circulation</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>2432</fpage>
          <lpage>9</lpage>
          <volume>109</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Dokainish</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Zoghbi</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Lakkis</surname>
              <given-names>NM</given-names>
            </name>
            <name>
              <surname>Al-Bakshy</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Dhir</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Quinones</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B47">
        <mixed-citation>47. Sharma R, Pellerin    D, Gaze DC, Mehta RL, Gregson H, Streather CP, et al Mitral peak Doppler E-wave    to peak mitral annulus velocity ratio is an accurate estimate of left ventricular    filling pressure and predicts mortality in end-stage renal disease. J Am Soc    Echocardiogr. 2006; 19: 266-73.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Mitral peak Doppler E-wave to peak mitral annulus velocity ratio is an accurate estimate of left ventricular filling pressure and predicts mortality in end-stage renal disease</article-title>
          <source>J Am Soc Echocardiogr</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>266</fpage>
          <lpage>73</lpage>
          <volume>19</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sharma</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Pellerin</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Gaze</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Mehta</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Gregson</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Streather</surname>
              <given-names>CP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B48">
        <mixed-citation>48. Wang AY, Wang    M, Lam CW, Chan IH, Zhang Y, Sanderson JE. Left ventricular filling pressure    by Doppler echocardiography in patients with end-stage renal disease. Hypertension.    2008; 52: 107-14.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Left ventricular filling pressure by Doppler echocardiography in patients with end-stage renal disease</article-title>
          <source>Hypertension</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>107</fpage>
          <lpage>14</lpage>
          <volume>52</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>AY</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lam</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>IH</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Sanderson</surname>
              <given-names>JE</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B49">
        <mixed-citation>49. Abhayaratna    WP, Seward JB, Appleton CP, Douglas PS, Oh JK, Tajik AJ, et al. Left atrial    size: physiologic determinants and clinical applications. J Am Coll Cardiol.    2006; 47: 2357-63.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Left atrial size: physiologic determinants and clinical applications</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>2357</fpage>
          <lpage>63</lpage>
          <volume>47</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Abhayaratna</surname>
              <given-names>WP</given-names>
            </name>
            <name>
              <surname>Seward</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Appleton</surname>
              <given-names>CP</given-names>
            </name>
            <name>
              <surname>Douglas</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Oh</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Tajik</surname>
              <given-names>AJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B50">
        <mixed-citation>50. Lester SJ,    Ryan EW, Schiller NB, Foster E. Best method in clinical practice and in research    studies to determine left atrial size. Am J Cardiol. 1999; 84: 829-32.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Best method in clinical practice and in research studies to determine left atrial size</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>829</fpage>
          <lpage>32</lpage>
          <volume>84</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lester</surname>
              <given-names>SJ</given-names>
            </name>
            <name>
              <surname>Ryan</surname>
              <given-names>EW</given-names>
            </name>
            <name>
              <surname>Schiller</surname>
              <given-names>NB</given-names>
            </name>
            <name>
              <surname>Foster</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B51">
        <mixed-citation>51. Lang RM, Bierig    M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations    for chamber quantification: a report from the American Society of Echocardiography's    Guidelines and Standards Committee and the Chamber Quantification Writing Group,    developed in conjunction with the European Association of Echocardiography,    a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;    18: 1440-63.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology</article-title>
          <source>J Am Soc Echocardiogr</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1440</fpage>
          <lpage>63</lpage>
          <volume>18</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lang</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Bierig</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Devereux</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Flachskampf</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Foster</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Pellikka</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B52">
        <mixed-citation>52. Tsang TS, Abhayaratna    WP, Barnes ME, Miyasaka Y, Gersh BJ, Bailey KR, et al. Prediction of cardiovascular    outcomes with left atrial size: is volume superior to area or diameter? J Am    Coll Cardiol. 2006; 47: 1018-23.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prediction of cardiovascular outcomes with left atrial size: is volume superior to area or diameter?</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>1018</fpage>
          <lpage>23</lpage>
          <volume>47</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Tsang</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Abhayaratna</surname>
              <given-names>WP</given-names>
            </name>
            <name>
              <surname>Barnes</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Miyasaka</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Gersh</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Bailey</surname>
              <given-names>KR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B53">
        <mixed-citation>53. Tsang TS, Barnes    ME, Gersh BJ, Bailey KR, Seward JB. Left atrial volume as a morphophysiologic    expression of left ventricular diastolic dysfunction and relation to cardiovascular    risk burden. Am J Cardiol. 2002; 90: 1284-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1284</fpage>
          <lpage>9</lpage>
          <volume>90</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Tsang</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Barnes</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Gersh</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Bailey</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Seward</surname>
              <given-names>JB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B54">
        <mixed-citation>54. Barberato SH,    Pecoits-Filho R. Usefulness of left atrial volume for the differentiation of    normal from pseudonormal diastolic function pattern in patients on hemodialysis.    J Am Soc Echocardiogr. 2007; 20: 359-65.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Usefulness of left atrial volume for the differentiation of normal from pseudonormal diastolic function pattern in patients on hemodialysis</article-title>
          <source>J Am Soc Echocardiogr</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>359</fpage>
          <lpage>65</lpage>
          <volume>20</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Barberato</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Pecoits-Filho</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B55">
        <mixed-citation>55. Tripepi G,    Benedetto FA, Mallamaci F, Tripepi R, Malatino L, Zoccali C. Left atrial volume    in end-stage renal disease: a prospective cohort study. J Hypertens. 2006; 24:    1173-80.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Left atrial volume in end-stage renal disease: a prospective cohort study</article-title>
          <source>J Hypertens</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>1173</fpage>
          <lpage>80</lpage>
          <volume>24</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Tripepi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Benedetto</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Mallamaci</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Tripepi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Malatino</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Zoccali</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B56">
        <mixed-citation>56. Wang AY, Woo    J, Wang M, Sea MM, Ip R, Li PK, et al. Association of inflammation and malnutrition    with cardiac valve calcification in continuous ambulatory peritoneal dialysis    patients. J Am Soc Nephrol. 2001; 12: 1927-36.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Association of inflammation and malnutrition with cardiac valve calcification in continuous ambulatory peritoneal dialysis patients</article-title>
          <source>J Am Soc Nephrol</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>1927</fpage>
          <lpage>36</lpage>
          <volume>12</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>AY</given-names>
            </name>
            <name>
              <surname>Woo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sea</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Ip</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>PK</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B57">
        <mixed-citation>57. Wang AY, Wang    M, Woo J, Lam CW, Li PK, Lui SF, et al. Cardiac valve calcification as an important    predictor for all-cause mortality and cardiovascular mortality in long-term    peritoneal dialysis patients: a prospective study. J Am Soc Nephrol. 2003; 14:    159-68.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study</article-title>
          <source>J Am Soc Nephrol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>159</fpage>
          <lpage>68</lpage>
          <volume>14</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>AY</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Woo</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Lam</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>PK</given-names>
            </name>
            <name>
              <surname>Lui</surname>
              <given-names>SF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B58">
        <mixed-citation>58. Sharma R, Chemla    E, Tome M, Mehta RL, Gregson H, Brecker SJ, et al. Echocardiography-based score    to predict outcome after renal transplantation. Heart. 2007; 93: 464-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Echocardiography-based score to predict outcome after renal transplantation</article-title>
          <source>Heart</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>464</fpage>
          <lpage>9</lpage>
          <volume>93</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sharma</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Chemla</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Tome</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mehta</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Gregson</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Brecker</surname>
              <given-names>SJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B59">
        <mixed-citation>59. Panuccio V,    Tripepi R, Tripepi G, Mallamaci F, Benedetto FA, Cataliotti A, et al. Heart    valve calcifications, survival, and cardiovascular risk in hemodialysis patients.    Am J Kidney Dis. 2004; 43: 479-84.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Heart valve calcifications, survival, and cardiovascular risk in hemodialysis patients</article-title>
          <source>Am J Kidney Dis</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>479</fpage>
          <lpage>84</lpage>
          <volume>43</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Panuccio</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Tripepi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Tripepi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Mallamaci</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Benedetto</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Cataliotti</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B60">
        <mixed-citation>60. Gunukula SR,    Spodick DH. Pericardial disease in renal patients. Semin Nephrol. 2001; 21:    52-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Pericardial disease in renal patients</article-title>
          <source>Semin Nephrol</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>52</fpage>
          <lpage>6</lpage>
          <volume>21</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gunukula</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Spodick</surname>
              <given-names>DH</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B61">
        <mixed-citation>61. Banerjee A,    Davenport A. Changing patterns of pericardial disease in patients with end-stage    renal disease. Hemodial Int. 2006; 10: 249-55.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Changing patterns of pericardial disease in patients with end-stage renal disease</article-title>
          <source>Hemodial Int</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>249</fpage>
          <lpage>55</lpage>
          <volume>10</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Banerjee</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Davenport</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B62">
        <mixed-citation>62. Bergeron S,    Hillis GS, Haugen EN, Oh JK, Bailey KR, Pellikka PA. Prognostic value of dobutamine    stress echocardiography in patients with chronic kidney disease. Am Heart J.    2007; 153: 385-91.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic value of dobutamine stress echocardiography in patients with chronic kidney disease</article-title>
          <source>Am Heart J</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>385</fpage>
          <lpage>91</lpage>
          <volume>153</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bergeron</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hillis</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Haugen</surname>
              <given-names>EN</given-names>
            </name>
            <name>
              <surname>Oh</surname>
              <given-names>JK</given-names>
            </name>
            <name>
              <surname>Bailey</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Pellikka</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B63">
        <mixed-citation>63. Rabbat CG,    Treleaven DJ, Russell JD, Ludwin D, Cook DJ. Prognostic value of myocardial    perfusion studies in patients with end-stage renal disease assessed for kidney    or kidney-pancreas transplantation: a meta-analysis. J Am Soc Nephrol. 2003;    14: 431-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic value of myocardial perfusion studies in patients with end-stage renal disease assessed for kidney or kidney-pancreas transplantation: a meta-analysis</article-title>
          <source>J Am Soc Nephrol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>431</fpage>
          <lpage>9</lpage>
          <volume>14</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rabbat</surname>
              <given-names>CG</given-names>
            </name>
            <name>
              <surname>Treleaven</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Russell</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Ludwin</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Cook</surname>
              <given-names>DJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B64">
        <mixed-citation>64. De Lima JJ,    Sabbaga E, Vieira ML, de Paula FJ, Ianhez LE, Krieger EM, et al. Coronary angiography    is the best predictor of events in renal transplant candidates compared with    noninvasive testing. Hypertension. 2003;42:263-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Coronary angiography is the best predictor of events in renal transplant candidates compared with noninvasive testing</article-title>
          <source>Hypertension</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>263</fpage>
          <lpage>8</lpage>
          <volume>42</volume>
          <person-group person-group-type="author">
            <name>
              <surname>De Lima</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Sabbaga</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Vieira</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>de Paula</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Ianhez</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Krieger</surname>
              <given-names>EM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B65">
        <mixed-citation>65. Dahan M, Viron    BM, Poiseau E, Kolta AM, Aubry N, Paillole C, et al. Combined dipyridamole-exercise    stress echocardiography for detection of myocardial ischemia in hemodialysis    patients: an alternative to stress nuclear imaging. Am J Kidney Dis. 2002; 40:    737-44.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Combined dipyridamole-exercise stress echocardiography for detection of myocardial ischemia in hemodialysis patients: an alternative to stress nuclear imaging</article-title>
          <source>Am J Kidney Dis</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>737</fpage>
          <lpage>44</lpage>
          <volume>40</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Dahan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Viron</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Poiseau</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Kolta</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Aubry</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Paillole</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B66">
        <mixed-citation>66. Cortigiani    L, Desideri A, Gigli G, Vallebona A, Terlizzi R, Giusti R, et al. Clinical,    resting echo and dipyridamole stress echocardiography findings for the screening    of renal transplant candidates. Int J Cardiol. 2005; 103: 168-74.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Clinical, resting echo and dipyridamole stress echocardiography findings for the screening of renal transplant candidates</article-title>
          <source>Int J Cardiol</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>168</fpage>
          <lpage>74</lpage>
          <volume>103</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cortigiani</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Desideri</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Gigli</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Vallebona</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Terlizzi</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Giusti</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B67">
        <mixed-citation>67. Ferreira PA,    de Lima VC, Campos Filho O, Gil MA, Cordovil A, Machado CV, et al. Feasibility,    safety and accuracy of dobutamine/atropine stress echocardiography for the detection    of coronary artery disease in renal transplant candidates. Arq Bras Cardiol.    2007; 88: 45-51.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Feasibility, safety and accuracy of dobutamine/atropine stress echocardiography for the detection of coronary artery disease in renal transplant candidates</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>45</fpage>
          <lpage>51</lpage>
          <volume>88</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ferreira</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>de Lima</surname>
              <given-names>VC</given-names>
            </name>
            <name>
              <surname>Campos Filho</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Gil</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Cordovil</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Machado</surname>
              <given-names>CV</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B68">
        <mixed-citation>68. K/DOQI Workgroup.    Clinical practice guidelines for cardiovascular disease in dialysis patients.    Am J Kidney Dis. 2005; 45: S1-153.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Clinical practice guidelines for cardiovascular disease in dialysis patients</article-title>
          <source>Am J Kidney Dis</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>S1</fpage>
          <lpage>153</lpage>
          <volume>45</volume>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories/>
      <title-group>
        <article-title xml:lang="es">Alteraciones ecocardiogr&#225;ficas en pacientes con insuficiencia renal cr&#243;nica en programa de hemodi&#225;lisis</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>Alteraciones de estructura y funci&#243;n card&#237;acas detectadas por ecocardiograf&#237;a son comunes en pacientes con enfermedad renal cr&#243;nica en hemodi&#225;lisis y predicen un peor pron&#243;stico. Esta revisi&#243;n aborda recientes evidencias de la utilidad del m&#233;todo en la detecci&#243;n de la disfunci&#243;n card&#237;aca cl&#237;nica y subcl&#237;nica, estratificaci&#243;n del riesgo cardiovascular y evaluaci&#243;n de las estrategias de intervenci&#243;n terap&#233;utica.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Ecocardiograf&#237;a doppler</kwd>
        <kwd>di&#225;lisis renal</kwd>
        <kwd>evaluaci&#243;n de riesgo</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO DE REVISI&#211;N</bold>
      </p>
      <p>
        <fn id="top-body2">
          <label>
            <bold>Alteraciones ecocardiogr&#225;ficas en pacientes con insuficiencia renal cr&#243;nica en programa de hemodi&#225;lisis</bold>
          </label>
          <p>
            <bold>Silvio Henrique Barberato; Roberto Pecoits-Filho</bold>
          </p>
        </fn>
      </p>
      <p>Pontificia Universidade Cat&#243;lica do Paran&#225;, Curitiba, PR - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p>Alteraciones de estructura y funci&#243;n card&#237;acas detectadas por ecocardiograf&#237;a son comunes en pacientes con enfermedad renal cr&#243;nica en hemodi&#225;lisis y predicen un peor pron&#243;stico. Esta revisi&#243;n aborda recientes evidencias de la utilidad del m&#233;todo en la detecci&#243;n de la disfunci&#243;n card&#237;aca cl&#237;nica y subcl&#237;nica, estratificaci&#243;n del riesgo cardiovascular y evaluaci&#243;n de las estrategias de intervenci&#243;n terap&#233;utica.</p>
      <p><bold>Palabras clave: </bold> Ecocardiograf&#237;a doppler, di&#225;lisis renal, evaluaci&#243;n de riesgo.</p>
      <p>
        <bold>Enfermedad renal cr&#243;nica y cardiopat&#237;a</bold>
      </p>
      <p>Las complicaciones cardiovasculares son la principal causa de &#243;bito de los pacientes portadores de enfermedad renal cr&#243;nica (ERC) en terapia de sustituci&#243;n renal mediante hemodi&#225;lisis<sup>1,2</sup>. La mortalidad cardiovascular en esos individuos es 10 a 20 veces m&#225;s frecuente que en la poblaci&#243;n general<sup>3</sup>. Aunque m&#225;s del 50% de los individuos que inician el programa de hemodi&#225;lisis presentan alguna forma de enfermedad cardiovascular preexistente<sup>4</sup>, los factores de riesgo tradicionales para enfermedad cardiovascular, no explican completamente ese exceso de riesgo, que parece ser influenciado por los llamados factores de riesgo no tradicionales, distintivos de la enfermedad renal cr&#243;nica<sup>1</sup>. El conjunto de esos factores acelera el curso de la enfermedad arterial coronaria<sup>5</sup> y se asocia con una mayor prevalencia de hipertrofia ventricular, fibrosis mioc&#225;rdica, valvulopat&#237;as, arritmias y muerte s&#250;bita<sup>6</sup>. La miocardiopat&#237;a del paciente en hemodi&#225;lisis se debe principalmente a la presencia de cardiopat&#237;a isqu&#233;mica - por obstrucci&#243;n cr&#237;tica de coronarias, reducci&#243;n de reserva coronaria o alteraciones microvasculares - y alteraciones morfofuncionales del ventr&#237;culo izquierdo (VI), en respuesta a la sobrecarga de presi&#243;n y de volumen<sup>7</sup>. La fisiopatolog&#237;a de las transformaciones inducidas por la uremia en la c&#225;mara ventricular izquierda es compleja y multifactorial.</p>
      <p>La sobrecarga de volumen proviene de la retenci&#243;n hidrosalina, anemia y f&#237;stula arteriovenosa, y lleva a la hipertrofia exc&#233;ntrica del VI (aumento de la masa secundario al aumento en la longitud del miocito y en el volumen ventricular, con el espesor relativo de la pared normal). La anemia, en particular, merece menci&#243;n especial en este grupo de pacientes. La asociaci&#243;n entre anemia, insuficiencia cardiaca congestiva e insuficiencia renal llev&#243; a Silverberg et al<sup>8</sup> a proponer el t&#233;rmino "s&#237;ndrome cardiorrenal"<sup>8</sup>. Afecciones del coraz&#243;n y del ri&#241;&#243;n pueden tener una etiolog&#237;a com&#250;n, y la insuficiencia cardiaca puede llevar a la uremia prerrenal; a su vez, la disminuci&#243;n de la funci&#243;n renal puede generar anemia, lo que lleva a mayores da&#241;os card&#237;acos. La correcci&#243;n del hematocrito con el empleo de la eritropoyetina gener&#243; beneficios cl&#237;nicos (mejora de la clase funcional y reducci&#243;n del requerimiento de diur&#233;ticos) y morfofisiol&#243;gicos (mejora en la remodelaci&#243;n y en la funci&#243;n ventricular izquierda)<sup>9</sup>.</p>
      <p>La sobrecarga de presi&#243;n puede ser consecuencia de la hipertensi&#243;n arterial, arteriosclerosis y, ocasionalmente, estenosis a&#243;rtica, causando hipertrofia conc&#233;ntrica del VI (aumento de la masa, secundario al aumento del espesor del miocito, sin modificaci&#243;n significativa en el volumen ventricular y con el espesor relativo aumentado). En ausencia de intervenciones que reduzcan la sobrecarga del VI, resulta comprometida la adaptaci&#243;n de la c&#225;mara con el consiguiente aumento de la muerte celular y de la fibrosis mioc&#225;rdica, que llevan a la disminuci&#243;n de la densidad capilar, disfunci&#243;n diast&#243;lica, trastornos de la conducci&#243;n intraventricular, dilataci&#243;n y m&#225;s hipertrofia compensadora<sup>10,11</sup>.</p>
      <p>Tales fen&#243;menos predisponen a la remodelaci&#243;n ventricular por activaci&#243;n neurohumoral y al aumento de la excitabilidad el&#233;ctrica, elementos crecientemente relacionados a la mayor incidencia de muerte s&#250;bita en este grupo de pacientes<sup>6</sup>. A&#250;n despu&#233;s del tratamiento medicamentoso optimizado y de los procedimientos de revascularizaci&#243;n coronaria, una parte de los pacientes de hemodi&#225;lisis sufre muerte s&#250;bita, lo que sugiere que otros factores, adem&#225;s de la isquemia mioc&#225;rdica, pueden ejercer un papel importante en el desencadenamiento de arritmias letales<sup>12</sup>.</p>
      <p>Potenciales sustratos para la g&#233;nesis de arritmias en este escenario cl&#237;nico incluyen: alteraciones metab&#243;licas, disfunci&#243;n sist&#243;lica y/o diast&#243;lica, hipertrofia ventricular izquierda y sobrecarga de volumen<sup>13</sup>. Paralelamente, ocurre el desv&#237;o hacia la izquierda de la curva de presi&#243;n-volumen del VI, lo que significa que peque&#241;os incrementos de volumen pueden desencadenar grandes elevaciones de presi&#243;n, con manifestaci&#243;n cl&#237;nica de insuficiencia cardiaca congestiva<sup>2</sup>. La muerte de los miocitos inducida por la agresi&#243;n conjunta de la sobrecarga hemodin&#225;mica combinada con los factores de riesgo propios de la uremia, como anemia, hiperparatiroidismo, desnutrici&#243;n, stress oxidativo e inflamaci&#243;n cr&#243;nica, entre otros, torna a&#250;n m&#225;s sombr&#237;o el pron&#243;stico.</p>
      <p>Si bien el diagn&#243;stico cl&#237;nico de insuficiencia cardiaca puede ser hecho con relativa seguridad, la interpretaci&#243;n de los signos cl&#237;nicos es un problema en la pr&#225;ctica diaria. Se sabe que la insuficiencia cardiaca cl&#237;nicamente manifiesta representa un predictor independiente de mortalidad en los pacientes que comienzan el tratamiento con hemodi&#225;lisis<sup>14</sup>, pero la comprensi&#243;n de la causa subyacente puede ser importante para direccionar la conducta terap&#233;utica. Algunas cuestiones, por lo tanto, se tornan relevantes en el manejo de esta poblaci&#243;n de alto riesgo: &#191;Hay una simple sobrecarga de volumen o una enfermedad cardiaca primaria? Habiendo cardiopat&#237;a, &#191;las funciones sist&#243;lica y/o diast&#243;lica est&#225;n comprometidas? &#191;Podemos estimar presiones de llenado del VI?</p>
      <p>En este contexto, la utilizaci&#243;n de m&#233;todos de investigaci&#243;n complementarios, t&#233;cnicamente simples, de bajo costo relativo y con buena reproductibilidad, contribuye en forma importante a la evoluci&#243;n del conocimiento de la fisiopatolog&#237;a de la enfermedad y a la evaluaci&#243;n de potenciales estrategias de tratamiento.</p>
      <p>
        <bold>Papel de la ecocardiograf&#237;a</bold>
      </p>
      <p>El diagn&#243;stico ecodopplercardiogr&#225;fico de las anormalidades del VI es un importante paso hacia la caracterizaci&#243;n de individuos con mayor riesgo cardiovascular, que estima la prevalencia de la enfermedad cardiaca primaria en una poblaci&#243;n para estudiar sus factores predisponentes, el impacto pron&#243;stico y el efecto de intervenciones terap&#233;uticas<sup>15</sup>. El ecocardiograma doppler es un examen complementario, no invasivo, ampliamente utilizado en la evaluaci&#243;n de la estructura y funci&#243;n card&#237;acas, que une varias t&#233;cnicas de ultrasonido en un solo examen. Tradicionalmente, el modo M y el bidimensional permiten evaluar la masa y los vol&#250;menes ventriculares, obteniendo excelente precisi&#243;n en el diagn&#243;stico de la hipertrofia, definici&#243;n de su modelo geom&#233;trico (conc&#233;ntrica o exc&#233;ntrica) y estimaci&#243;n de la funci&#243;n sist&#243;lica (de forma cualitativa o cuantitativa).</p>
      <p>Adem&#225;s, las t&#233;cnicas derivadas del doppler pueden generar informaciones indirectas respecto del relajamiento ventricular y de su din&#225;mica de llenado, que constituyen la fisiolog&#237;a de la di&#225;stole. En un estudio canadiense que realiz&#243; el seguimiento de 432 pacientes que iniciaban hemodi&#225;lisis, solamente el 16% ten&#237;an un ecocardiograma doppler normal<sup>16</sup>. El hallazgo de las alteraciones ecocardiogr&#225;ficas - como hipertrofia, dilataci&#243;n y disfunci&#243;n sist&#243;lica -, triplica el riesgo de insuficiencia cardiaca, independientemente de la edad, diabetes e insuficiencia coronaria<sup>16</sup>.</p>
      <p>
        <bold>Hipertrofia ventricular izquierda</bold>
      </p>
      <p>La hipertrofia ventricular izquierda (HVI) es altamente prevalente en la ERC y se asocia a un pron&#243;stico francamente desfavorable. M&#225;s de dos tercios de los pacientes en di&#225;lisis con HVI mueren de insuficiencia cardiaca congestiva o muerte s&#250;bita<sup>17</sup>, raz&#243;n por la cual es uno de los blancos principales para la intervenci&#243;n terap&#233;utica, junto con la enfermedad arterial coronaria. La incidencia de HVI aumenta con el progresivo deterioro de la funci&#243;n renal, y existe una correlaci&#243;n lineal inversa entre la masa ventricular izquierda y la tasa de filtrado glomerular<sup>18</sup>. As&#237;, la prevalencia de HVI oscila entre el 16% y el 31% en individuos con ERC y filtrado glomerular &gt; 30 ml/min; entre el 38% y el 45% en aquellos con funci&#243;n renal m&#225;s comprometida<sup>18,19</sup>; entre el 60% y el 75% en los que iniciaron terapia de substituci&#243;n renal; alcanzando el 70% a 90% en pacientes bajo tratamiento regular con hemodi&#225;lisis<sup>14,20,21</sup>.</p>
      <p>La masa del VI es proporcional al tama&#241;o corporal y, tradicionalmente, se utiliz&#243; la indexaci&#243;n por la superficie corporal como correcci&#243;n en los estudios cl&#225;sicos. Diferentes valores fueron empleados en diversos estudios prospectivos para la definici&#243;n de la presencia de HVI. Como ejemplos, Silberberg et al<sup>22</sup> usaron como valor de referencia 125 g/m<sup>2</sup>, mientras que Parfrey et al<sup>16</sup> usaron los valores empleados en el estudio de Framingham (132 g/m<sup>2</sup> para hombres y 100 g/m<sup>2</sup> para mujeres). A pesar de esa variaci&#243;n, todos tuvieron resultados semejantes, demostrando el claro efecto de la masa ventricular aumentada en el pron&#243;stico adverso<sup>16,22,23</sup>. No obstante, el individuo en hemodi&#225;lisis est&#225; sujeto a grandes variaciones en el peso corporal, sea por las alteraciones de la volemia, sea por el compromiso del estado nutricional, lo que puede llevar a errores de evaluaci&#243;n basados en la indexaci&#243;n por la superficie corporal.</p>
      <p>As&#237;, la indexaci&#243;n por la altura elevada a la potencia de 2,7, propuesta por de Simone et al<sup>24</sup>, parece ser la m&#225;s acertada para la estimaci&#243;n de la masa del VI en este grupo de pacientes. Aplicando ese concepto en pacientes de hemodi&#225;lisis, se demostr&#243; que el m&#233;todo basado en la altura tiene, para la predicci&#243;n de la mortalidad general y cardiovascular, un valor ligeramente superior al que se basa en la superficie corporal<sup>25</sup>. Es importante reconocer que, parte de las alteraciones en la geometr&#237;a del VI en pacientes ur&#233;micos, puede estar relacionada al momento en que se realiza el ecocardiograma. Inmediatamente despu&#233;s de la sesi&#243;n de di&#225;lisis, es com&#250;n encontrar una reducci&#243;n del di&#225;metro diast&#243;lico del VI y aumento del espesor de la pared, como consecuencias de la depleci&#243;n de volumen por el ultrafiltrado.</p>
      <p>De la misma manera, el examen realizado inmediatamente antes de iniciar la sesi&#243;n puede diagnosticar dilataci&#243;n del VI con hipertrofia exc&#233;ntrica, la que se "convertir&#225;" en conc&#233;ntrica al final de la sesi&#243;n. Tales fluctuaciones pueden llevar a errores de evaluaci&#243;n, que pueden ser minimizados realizando el examen en un d&#237;a interdial&#237;tico (martes o jueves), preferentemente entre las 12 y las 18 horas<sup>16</sup>.</p>
      <p>A pesar de que la HVI diagnosticada por ecocardiograma es un predictor independiente de mortalidad universalmente reconocido, es importante resaltar que esa condici&#243;n se obtiene tras un per&#237;odo de por lo menos dos a&#241;os bajo tratamiento con di&#225;lisis. La estratificaci&#243;n adicional puede obtenerse mediante la categorizaci&#243;n del modelo geom&#233;trico de la hipertrofia mioc&#225;rdica, o sea, conc&#233;ntrica o exc&#233;ntrica<sup>23</sup>. Un estudio prospectivo multic&#233;ntrico de 432 pacientes que iniciaban hemodi&#225;lisis mostr&#243; un tiempo promedio de sobrevida de 48 meses para portadores de HVI conc&#233;ntrica y de 56 meses para la exc&#233;ntrica<sup>14,23</sup>.</p>
      <p>El monitoreo de la masa por medio del ecocardiograma seriado es una herramienta cl&#237;nica adicional de gran importancia para la evaluaci&#243;n del pron&#243;stico y del &#233;xito de las intervenciones tendientes a la regresi&#243;n de la HVI<sup>26</sup>. Evidencias indican que la progresi&#243;n de la HVI en individuos con ERC es predictora de eventos cardiovasculares, independientemente de los valores basales de la masa ventricular izquierda<sup>27</sup>. Por otro lado, la regresi&#243;n de la hipertrofia mioc&#225;rdica puede lograrse con un tratamiento farmacol&#243;gico potente, en especial con inhibidores de la enzima convertidora de la angiotensina-II, resultando en una reducci&#243;n del n&#250;mero de eventos cardiovasculares y en una mayor sobrevida<sup>21</sup>. Otras estrategias de regresi&#243;n de la HVI en la ERC terminal, como el tratamiento con eritropoyetina, control estricto de la volemia por ultrafiltrado agresivo y trasplante renal, pueden tambi&#233;n tener sus efectos monitoreados por ecocardiograf&#237;a.</p>
      <p>
        <bold>Disfunci&#243;n sist&#243;lica del ventr&#237;culo izquierdo</bold>
      </p>
      <p>En estudios que utilizaban diferentes metodolog&#237;as, la prevalencia de la disfunci&#243;n sist&#243;lica del VI vari&#243; del 15% al 18% en pacientes de hemodi&#225;lisis (iniciando el tratamiento<sup>28</sup> o en terapia cr&#243;nica regular<sup>29</sup>, respectivamente), llegando hasta el 28% en individuos evaluados en el momento del trasplante renal<sup>20</sup>. La disfunci&#243;n sist&#243;lica del VI es un poderoso indicador de pron&#243;stico desfavorable para individuos en programa de hemodi&#225;lisis<sup>23</sup>, as&#237; como tras el trasplante renal<sup>20</sup>. Los mecanismos responsables son multifactoriales, e incluyen insuficiencia coronaria, anemia, hiperparatiroidismo, toxinas ur&#233;micas, malnutrici&#243;n y sobrecarga hemodin&#225;mica prolongada<sup>30</sup>. El an&#225;lisis de la funci&#243;n sist&#243;lica del VI mediante ecocardiograma se realiza usualmente por m&#233;todos que eval&#250;an la fase de eyecci&#243;n, especialmente el acortamiento porcentual y la fracci&#243;n de eyecci&#243;n. Esas t&#233;cnicas, basadas en mediciones hechas en el endocardio, pueden sobrestimar la contractilidad en pacientes con HVI.</p>
      <p>Alternativamente, un m&#233;todo basado en la medici&#243;n de la fracci&#243;n de acortamiento de la pared mioc&#225;rdica (<italic>midwall fractional shortening</italic>), propuesto como medici&#243;n de la funci&#243;n sist&#243;lica independiente de la geometr&#237;a del VE<sup>31</sup>, puede ser empleado en este contexto, diagnosticando un menor desempe&#241;o sist&#243;lico en individuos con fracci&#243;n de eyecci&#243;n normal. Pese a tales ponderaciones, la disfunci&#243;n sist&#243;lica del VE, diagnosticada por cualquiera de los m&#233;todos mencionados, que no se diferenciaron en el poder predictivo, se asoci&#243; de modo independiente a eventos cardiovasculares fatales y no fatales<sup>32</sup>.</p>
      <p>Es interesante resaltar que, a&#250;n cuando el efecto adverso de la disfunci&#243;n sist&#243;lica sea independiente de la masa ventricular izquierda, estas alteraciones interact&#250;an en la predicci&#243;n de eventos cardiovasculares, alcanzando el riesgo m&#225;ximo en los pacientes con asociaci&#243;n de ambas<sup>32</sup>.</p>
      <p>
        <bold>Disfunci&#243;n diast&#243;lica del ventr&#237;culo izquierdo</bold>
      </p>
      <p>La disfunci&#243;n diast&#243;lica se caracteriza por alteraciones de la relajaci&#243;n y la complacencia ventricular, y cursa frecuentemente con aumento compensatorio de las presiones de llenado en fases m&#225;s avanzadas. Desde el punto de vista hemodin&#225;mico, el aumento de la presi&#243;n diast&#243;lica intraventricular izquierda es el fen&#243;meno responsable de la manifestaci&#243;n de la insuficiencia cardiaca, cualquiera sea la causa subyacente<sup>33</sup>.</p>
      <p>Estudios de necropsia y uremia experimental mostraron la presencia de fibrosis intermiocardioc&#237;tica difusa espec&#237;fica en el coraz&#243;n de individuos ur&#233;micos, no observada en hipertensos sin nefropat&#237;a, lo que podr&#237;a implicar inestabilidad el&#233;ctrica (predisponiendo a la muerte s&#250;bita) y alteraciones de las propiedades diast&#243;licas del miocardio (predisponiendo a la elevaci&#243;n de las presiones de llenado)<sup>10,34</sup>.</p>
      <p>Entre los mecanismos fisiopatol&#243;gicos relacionados a la fibrosis mioc&#225;rdica prominente, se postula la activaci&#243;n de factores humorales asociados a la hipertrofia - elevados niveles de angiotensina II, hormona paratiroidea, endotelina, aldosterona y catecolaminas plasm&#225;ticas - y a la presencia de isquemia mioc&#225;rdica subyacente<sup>13,34</sup>. El aumento de la rigidez y la disminuci&#243;n de la relajaci&#243;n (secundarios a la fibrosis) llevan a la exacerbaci&#243;n de los efectos de las variaciones vol&#233;micas sobre el llenado del VI.</p>
      <p>As&#237;, a&#250;n en pacientes con fracci&#243;n de eyecci&#243;n normal, un peque&#241;o aumento en el volumen ventricular izquierdo puede generar congesti&#243;n pulmonar, mientras que la depleci&#243;n vol&#233;mica puede inducir la disminuci&#243;n en el llenado de la c&#225;mara, ocasionando hipotensi&#243;n arterial e inestabilidad hemodin&#225;mica<sup>2</sup>. Se configura, entonces, la importancia de estimar adecuadamente no s&#243;lo la funci&#243;n sist&#243;lica del VI, sino tambi&#233;n la funci&#243;n diast&#243;lica, cuyas alteraciones pueden desencadenar episodios de edema agudo de pulm&#243;n e hipotensi&#243;n intradial&#237;tica<sup>2,35</sup>.</p>
      <p>Estudios con casu&#237;sticas reducidas informaron una prevalencia de disfunci&#243;n diast&#243;lica del VI en pacientes ur&#233;micos, que var&#237;a del 50% al 65%, incluyendo poblaciones predi&#225;lisis, en di&#225;lisis y postrasplante<sup>17</sup>. A&#250;n cuando las alteraciones del llenado ventricular izquierdo se detecten frecuentemente en los pacientes en hemodi&#225;lisis, la prevalencia de la disfunci&#243;n diast&#243;lica y su significado pron&#243;stico no son totalmente conocidos en este grupo<sup>13,36</sup>. Las limitaciones de la utilizaci&#243;n de par&#225;metros ecodopplercardiogr&#225;ficos derivados del flujo transvalvular mitral en estudios previos<sup>14,37</sup> se deben a que estos &#237;ndices son altamente dependientes de las condiciones de precarga<sup>38-40</sup>. Tal abordaje puede producir resultados falso-negativos en pacientes hemodializados, diagnosticando como normales a portadores de pseudonormalizaci&#243;n del flujo mitral (altas presiones de llenado que enmascaran la alteraci&#243;n en la relajaci&#243;n del ventr&#237;culo izquierdo).</p>
      <p>En este contexto, los nuevos &#237;ndices ecodopplercardiogr&#225;ficos empleados en la evaluaci&#243;n de la funci&#243;n cardiaca representan un avance importante en el diagn&#243;stico. En los &#250;ltimos a&#241;os, se introdujo en el escenario cl&#237;nico el doppler tisular (DT) del anillo mitral, como un importante m&#233;todo de evaluaci&#243;n de la funci&#243;n diast&#243;lica segmentaria y global del VI. La velocidad diast&#243;lica precoz del anillo mitral (E') se correlaciona bien con &#237;ndices de relajaci&#243;n estimados por m&#233;todos invasivos<sup>41,42</sup>. Algunos investigadores demostraron que las velocidades diast&#243;licas derivadas del doppler tisular del anillo mitral (E' y A') son "relativamente" independientes de la precarga, y que no existe variaci&#243;n significativa luego de una sesi&#243;n de hemodi&#225;lisis, si se respetan ciertos l&#237;mites "fisiol&#243;gicos" de reducci&#243;n vol&#233;mica, o sea, incapaces de desencadenar alteraciones de la frecuencia cardiaca y la presi&#243;n arterial<sup>39,43</sup>. Por ese motivo, E&#180; parece ser particularmente &#250;til en pacientes de hemodi&#225;lisis, identificando la alteraci&#243;n de la relajaci&#243;n independiente de las presiones de llenado del VI y, consecuentemente, diferenciando la pseudonormalizaci&#243;n del verdadero patr&#243;n normal de funci&#243;n diast&#243;lica<sup>39</sup>.</p>
      <p>Un estudio australiano reciente realiz&#243; el seguimiento de 129 pacientes con ERC terminal (sin evidencia de isquemia del VI en el ecocardiograma de stress) por m&#225;s de dos a&#241;os, evidenciando que la velocidad diast&#243;lica tisular sum&#243; un valor pron&#243;stico independiente de los par&#225;metros cl&#237;nicos<sup>44</sup>. La relaci&#243;n entre la velocidad diast&#243;lica precoz del flujo mitral (E) y E' (conocida como relaci&#243;n E/E') fue el mejor predictor no invasivo de elevaci&#243;n de las presiones de llenado en la comparaci&#243;n entre m&#250;ltiples &#237;ndices ecodopplercardiogr&#225;ficos y la presi&#243;n diast&#243;lica final (medida por cat&#233;ter de hemodinamia), sea usando E' septal<sup>45</sup>, sea usando el promedio de E' septal y lateral<sup>46</sup>. De esa forma, la relaci&#243;n E/E' es un &#237;ndice especialmente interesante para el diagn&#243;stico de la disfunci&#243;n diast&#243;lica avanzada. La posibilidad de indicar la elevaci&#243;n de la presi&#243;n intraventricular por medio de ese m&#233;todo permiti&#243;, en paralelo, la demostraci&#243;n de su importante valor pron&#243;stico en dos estudios recientes que abordaban a pacientes con ERC terminal.</p>
      <p>Un estudio con 125 candidatos al trasplante renal demostr&#243; que la relaci&#243;n E/E' &gt; 15 fue predictor independiente del aumento de la presi&#243;n diast&#243;lica del VI (superior a 15 mmHg) y se asoci&#243; a una mayor mortalidad general en este grupo<sup>47</sup>. Otro estudio, que abord&#243; a 220 individuos con ERC terminal con un seguimiento de cuatro a&#241;os, concluy&#243; que la relaci&#243;n E/E' &gt; 15 fue predictor independiente de mortalidad general y cardiovascular, adicionando m&#225;s informaci&#243;n pron&#243;stica, adem&#225;s de los datos cl&#237;nicos, bioqu&#237;micos, masa ventricular y funci&#243;n sist&#243;lica<sup>48</sup>.</p>
      <p>
        <bold>Dilataci&#243;n de la aur&#237;cula izquierda</bold>
      </p>
      <p>Fuertes evidencias apuntan la dilataci&#243;n de la aur&#237;cula izquierda (AI) como un s&#243;lido predictor de eventos cardiovasculares en la poblaci&#243;n general y en diversos escenarios cl&#237;nicos<sup>49</sup>. Directrices recientes recomiendan que la adecuada cuantificaci&#243;n del tama&#241;o de la AI sea obtenida mediante la estimaci&#243;n del volumen de la c&#225;mara en el modo bidimensional y no por la medici&#243;n tradicional del di&#225;metro anteroposterior del modo M<sup>50,51</sup>. Adem&#225;s de ser superior en la predicci&#243;n de eventos cardiovasculares - incluyendo fibrilaci&#243;n auricular, accidente cerebrovascular, insuficiencia cardiaca, infarto de miocardio y muerte card&#237;aca<sup>52</sup> -, el volumen de la AI est&#225; relacionado a la gravedad y la duraci&#243;n de la disfunci&#243;n diast&#243;lica del VI<sup>53</sup>. A diferencia de los &#237;ndices derivados del doppler convencional (flujo mitral) o tisular (anillo mitral), que nos proporcionan informaci&#243;n moment&#225;nea y transitoria respecto del llenado ventricular izquierdo, el volumen de la AI funciona como un marcador cr&#243;nico de la funci&#243;n diast&#243;lica, reflejando el promedio "hist&#243;rico" de las presiones de llenado aumentadas<sup>53</sup>.</p>
      <p>Un estudio reciente con pacientes de hemodi&#225;lisis con ritmo sinusal y sin valvulopat&#237;a mitral demostr&#243; que el volumen de la AI indexado para la superficie corporal &gt; 35 ml/m<sup>2</sup> fue el par&#225;metro m&#225;s exacto para la detecci&#243;n de la seudonormalizaci&#243;n del flujo mitral, en comparaci&#243;n con diversos &#237;ndices probados previamente<sup>54</sup>. Ampliando el valor cl&#237;nico del volumen de la AI, dos publicaciones recientes encontraron, utilizando m&#233;todos de indexaci&#243;n diferentes (superficie corporal<sup>29</sup> o altura elevada a la potencia 2,7<sup>55</sup>), que el &#237;ndice fue predictor independiente de mortalidad en pacientes con tratamiento renal sustitutivo. El hallazgo del volumen de la AI indexado &gt; 32 ml/m<sup>2</sup> suministr&#243; informaci&#243;n complementaria a los datos cl&#237;nicos y ecocardiogr&#225;ficos tradicionales, incluyendo fracci&#243;n de eyecci&#243;n, relaci&#243;n E/E' y masa ventricular izquierda<sup>29</sup>.</p>
      <p>Aun cuando sean necesarios nuevos estudios observacionales y de intervenci&#243;n para la validaci&#243;n de esos hallazgos y la definici&#243;n del mejor m&#233;todo de indexaci&#243;n en pacientes con nefropat&#237;as, es recomendable que la medici&#243;n del volumen de la AI sea incorporada a la evaluaci&#243;n ecocardiogr&#225;fica de rutina de esos pacientes, toda vez que el consenso de la Sociedad Americana de Ecocardiograf&#237;a ya la aconseja en la poblaci&#243;n general<sup>51</sup>. Como la funci&#243;n diast&#243;lica del VI parece estar cr&#243;nicamente comprometida en la mayoria de los pacientes de hemodi&#225;lisis, a&#250;n en aquellos que se presentan asintom&#225;ticos<sup>13</sup>, el volumen de la AI puede ofrecer la oportunidad de vislumbrar los individuos con mayor riesgo de manifestar insuficiencia cardiaca, arritmias auriculares y mala evoluci&#243;n cl&#237;nica.</p>
      <p>
        <bold>Calcificaciones valvulares</bold>
      </p>
      <p>La calcificaci&#243;n de las v&#225;lvulas card&#237;acas es frecuente en pacientes cr&#243;nicamente tratados con di&#225;lisis. Algunos datos sugieren que la calcificaci&#243;n valvular no sea solamente consecuencia del envejecimiento natural y de trastornos del metabolismo de calcio-f&#243;sforo, sino que tambi&#233;n resulte de la inflamaci&#243;n, semejante a la observada en la aterosclerosis<sup>56</sup>. Adem&#225;s de poder repercutir cl&#237;nicamente determinando reflujo y/o estenosis valvular, su importancia reside en la asociaci&#243;n que se ha relatado entre la calcificaci&#243;n valvular y un mayor riesgo de mortalidad y eventos cardiovasculares en el paciente ur&#233;mico.</p>
      <p>Un estudio realizado en 192 pacientes de di&#225;lisis peritoneal encontr&#243; calcificaci&#243;n en por lo menos una v&#225;lvula, mitral o a&#243;rtica, en el 32% de la poblaci&#243;n<sup>57</sup>. Tras un seguimiento promedio de 18 meses, la mortalidad cardiovascular fue del 22% contra el 3% en individuos con y sin calcificaci&#243;n valvular, respectivamente. Tal asociaci&#243;n fue independiente de las variables cl&#237;nicas y demogr&#225;ficas usuales, prote&#237;na C-reactiva y enfermedad vascular ateroscler&#243;tica concomitante<sup>57</sup>.</p>
      <p>Otro interesante estudio propuso un escore de predicci&#243;n del pron&#243;stico luego del trasplante renal basado en el ecocardiograma. Tras el seguimiento de 203 pacientes trasplantados (edad promedio de 47 &#177; 12 a&#241;os, el 93 % de ellos en di&#225;lisis), los predictores independientes de mortalidad fueron: edad <underline>&gt;</underline> 50 a&#241;os; dimensi&#243;n sist&#243;lica del VI <underline>&gt;</underline> 35 mm; espesor de pared <underline>&gt;</underline> 14 mm; y presencia de calcificaci&#243;n del anillo mitral<sup>58</sup>. Pacientes con edad <underline>&gt;</underline> 50 a&#241;os y dos de los otros tres predictores tuvieron una mortalidad del 82%<sup>58</sup>, en cinco a&#241;os. En contraste con esos hallazgos, un estudio realizado con 202 de pacientes de hemodi&#225;lisis (con prevalencia del 23% de calcificaci&#243;n valvular) no demostr&#243; valor pron&#243;stico independiente luego del ajuste para factores de riesgo y masa del ventr&#237;culo izquierdo<sup>59</sup>.</p>
      <p>
        <bold>Enfermedad peric&#225;rdica</bold>
      </p>
      <p>La pericarditis aguda puede ocurrir en aproximadamente el 20% de los pacientes ur&#233;micos, antes del inicio de la di&#225;lisis o durante la di&#225;lisis cr&#243;nica<sup>60</sup>. Uremia y/o di&#225;lisis ineficiente son las causas m&#225;s frecuentes. Individuos en hemodi&#225;lisis de mantenimiento, con derrame peric&#225;rdico importante, usualmente no responden en forma satisfactoria a la intensificaci&#243;n de la di&#225;lisis y pueden ser derivados al drenaje peric&#225;rdico electivo precoz en el intento de evitar complicaciones hemodin&#225;micas<sup>61</sup>. La pericarditis constrictiva ocurre menos frecuentemente en pacientes en hemodi&#225;lisis.</p>
      <p>
        <bold>Ecocardiograf&#237;a de estr&#233;s</bold>
      </p>
      <p>La utilizaci&#243;n de la ecocardiograf&#237;a de estr&#233;s farmacol&#243;gico en los portadores de ERC terminal es una estrategia bastante atrayente, toda vez que posibilita la b&#250;squeda de isquemia mioc&#225;rdica sin exigir del paciente la capacidad de ejercicio y proporciona adicionalmente una estimaci&#243;n de la funci&#243;n sist&#243;lica basal del VI. Adem&#225;s, la presencia y extensi&#243;n de la isquemia durante el examen tiene valor pron&#243;stico independiente para mortalidad general en ese grupo de individuos<sup>62</sup>. El uso de la dobutamina como agente estresante gener&#243; un mayor n&#250;mero de evidencias. El conjunto de informaciones disponibles no provee diferencias significativas de precisi&#243;n y valor predictivo negativo en comparaci&#243;n con la medicina nuclear, cuando se investiga enfermedad coronaria obstructiva en candidatos al trasplante renal (incluyendo aquellos en di&#225;lisis)<sup>63,64</sup>.</p>
      <p>Alternativamente, dos peque&#241;os estudios sugirieron la utilidad del ecocardiograma de estr&#233;s con dipiridamol en el diagn&#243;stico de la isquemia<sup>65</sup> y en la predicci&#243;n del pron&#243;stico<sup>66</sup>. Aun cuando pacientes con ERC y ecocardiograma de estr&#233;s normal tengan mejor pron&#243;stico que aquellos con estudio anormal, la tasa de mortalidad es importante en el primer grupo<sup>62</sup>, si comparamos con el excelente pron&#243;stico suministrado por el test normal en la poblaci&#243;n general, lo que puede ser explicado por el perfil de alto riesgo propio del individuo nefr&#243;pata.</p>
      <p>Adem&#225;s, un estudio nacional se&#241;al&#243; que el examen posee una limitada sensibilidad en la vigencia de enfermedad uniarterial coronaria y obstrucciones entre el 50% y el 70% de la luz del vaso<sup>67</sup>. As&#237;, el abordaje individualizado debe ser ponderado en individuos con mayor riesgo, pues la cinecoronariograf&#237;a puede ser a&#250;n de fundamental importancia en la detecci&#243;n de enfermedad arterial coronaria cl&#237;nicamente relevante<sup>64</sup>.</p>
      <p>
        <bold>Conclusi&#243;n</bold>
      </p>
      <p>El conjunto de evidencias indica el extraordinario papel de la ecodopplercardiograf&#237;a en la mejora de la calidad de la evaluaci&#243;n cl&#237;nica global del paciente con ERC en di&#225;lisis. La literatura y la pr&#225;ctica cl&#237;nica actuales vienen resaltando la utilidad del m&#233;todo en el diagn&#243;stico de la disfunci&#243;n cardiaca subcl&#237;nica, en el perfeccionamiento del diagn&#243;stico cl&#237;nico de insuficiencia cardiaca, en la predicci&#243;n del riesgo cardiovascular y en el direccionamiento y seguimiento de las estrategias terap&#233;uticas. Los eventos de ecocardiograf&#237;a doppler est&#225;n resultando como marcadores sustitutos &#250;tiles para estudios de pron&#243;stico e intervenci&#243;n. Directrices norteamericanas recomiendan el ecocardiograma doppler para todos los pacientes de di&#225;lisis, uno a tres meses luego del inicio de la terapia renal sustitutiva y, a continuaci&#243;n, en intervalos de tres a&#241;os, independientemente de los s&#237;ntomas<sup>68</sup>. Nuestra opini&#243;n tambi&#233;n es que todo paciente que comienza el tratamiento de hemodi&#225;lisis debe ser sometido al ecocardiograma.</p>
      <p>Por otra parte, intervalos menores entre los ex&#225;menes pueden ser de valor cl&#237;nico en conductas individualizadas. Est&#225; comprobado que el seguimiento con ecocardiogramas seriados agrega valor pron&#243;stico adem&#225;s del examen basal, posibilitando el control de la regresi&#243;n o no de las alteraciones del VI<sup>26</sup>. En el futuro, nuevos m&#233;todos de ecocardiograma doppler con la propiedad de investigar enfermedad mioc&#225;rdica subcl&#237;nica - como <italic>strain, strain rate</italic> y caracterizaci&#243;n ultras&#243;nica tisular -, podr&#225;n beneficiar a&#250;n m&#225;s ese grupo de pacientes con excesivo riesgo cardiovascular.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio no tuvo fuentes de financiaci&#243;n externas.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>No hay vinculaci&#243;n de este estudio a programas de postgrado.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Echocardiographic alterations in patients with chronic kidney failure undergoing hemodialysis</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>Changes in cardiac structure and function detected by echocardiography are common in patients with chronic kidney disease undergoing hemodialysis, and have been recognized as key outcome predictors. This review attempts to summarize recent evidence pointing to the usefulness of the method in the detection of clinical and subclinical cardiac dysfunction, stratification of cardiovascular risk and assessment of intervention strategies.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Echocardiography</kwd>
        <kwd>Doppler</kwd>
        <kwd>Renal Dialysis</kwd>
        <kwd>Risk Assessment</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>REVIEW ARTICLE</bold>
      </p>
      <p>
        <fn id="top-body3">
          <label>
            <bold>Echocardiographic alterations in patients with chronic kidney failure undergoing hemodialysis</bold>
          </label>
          <p>
            <bold>Silvio Henrique Barberato; Roberto Pecoits-Filho</bold>
          </p>
        </fn>
      </p>
      <p>Pontif&#237;cia Universidade Cat&#243;lica do Paran&#225;, Curitiba, PR, Brasil</p>
      <p>Mailing address</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p>Changes in cardiac structure and function detected by echocardiography are common in patients with chronic kidney disease undergoing hemodialysis, and have been recognized as key outcome predictors. This review attempts to summarize recent evidence pointing to the usefulness of the method in the detection of clinical and subclinical cardiac dysfunction, stratification of cardiovascular risk and assessment of intervention strategies.</p>
      <p><bold>Key-Word</bold>s: Echocardiography, Doppler; Renal Dialysis; Risk Assessment.</p>
      <p>
        <bold>Chronic Kidney Disease and Cardiopathy</bold>
      </p>
      <p>Cardiovascular complications are the main cause of death in patients with chronic kidney disease (CKD) undergoing hemodialysis therapy<sup>1,2</sup>. The cardiovascular mortality in these individuals is 10- to 20-fold more frequent than in the general population<sup>3</sup>. Although more than 50% of the individuals starting a dialysis program present some type of pre-existent cardiovascular disease<sup>4</sup>, the traditional risk factors for cardiovascular disease do not completely explain this excess risk, which seems to be influenced by the so-called non-traditional risk factors associated with CKD<sup>1</sup>. This set of factors accelerates the course of coronary artery disease (CAD)<sup>5</sup> and is associated with a higher prevalence of ventricular hypertrophy, myocardial fibrosis, valvulopathies, arrhythmias and sudden death<sup>6</sup>. The cardiomiopathy of the patient undergoing dialysis is mainly due to the presence of ischemic cardiopathy (by critical obstruction of the coronaries, decrease in coronary reserve or microvascular alterations) and morphofunctional alterations of the left ventricle (LV) in response to pressure and volume overload<sup>7</sup>. The physiopathology of the transformations induced by uremia in the left ventricular chamber is complex and multifactorial.</p>
      <p>The volume overload originates from the hydro-saline retention, anemia and arteriovenous fistula, leading to LV eccentric hypertrophy (mass increase secondary to the increase in myocyte length and increase in the ventricular volume, with normal relative wall thickness). Anemia, in particular, deserves special attention in this group of patients. The association between anemia, congestive heart failure and kidney failure led Silverberg et al<sup>8</sup> to propose the term "cardio-renal syndrome"<sup>8</sup>. Affections of the heart and kidney can have a common etiology and the heart failure (HF) can lead to pre-renal uremia; subsequently, the decrease in the renal function can cause anemia, which leads to more cardiac damage. The correction of the hematocrit using erythropoietin generated clinical (improvement in the functional class and decrease in the need for diuretics) and morphophysiological benefits (improvement in the LV remodeling and function)<sup>9</sup>.</p>
      <p>The overload of pressure can result from arterial hypertension, arteriosclerosis and, occasionally, aortic stenosis, causing LV concentric hypertrophy (increase in mass secondary to the increase in myocyte thickness, without significant alteration in the ventricular volume and increased relative thickness). In the absence of interventions that decrease the left ventricular overload, an impairment in the chamber adaptation occurs, with a consequent increase in cell death and myocardial fibrosis, which lead to capillary density decrease, diastolic dysfunction, intraventricular conduction disorders, dilatation and further compensatory hypertrophy<sup>10,11</sup>.</p>
      <p>Such phenomena predispose to ventricular remodeling by neurohumoral activation and increase in the electrical excitability, elements that are progressively associated to a higher incidence of sudden death in this group of patients<sup>6</sup>. Even after optimized pharmacological treatment and coronary revascularization procedures, some patients undergoing hemodialysis die of sudden death, suggesting that other factors, in addition to myocardial ischemia, can have an important role in the triggering of lethal arrhythmias<sup>12</sup>.</p>
      <p>Potential substrates for the genesis of arrhythmias in this clinical scenario include metabolic alterations, systolic and/or diastolic dysfunction, LV hypertrophy and volume overload<sup>13</sup>. In parallel, there is a displacement of LV pressure-volume curve to the left, meaning that small volume increases can trigger large pressure elevations, with clinical manifestations of congestive heart failure<sup>2</sup>. The myocyte death induced by the combined injury of hemodynamic overload and risk factors inherent to uremia, such as anemia, hyperparathyroidism, malnutrition, oxidative stress, chronic inflammation and others, makes the prognosis poorer. Although the clinical diagnosis of heart failure (HF) can be attained with relative safety, the interpretation of clinical signs is a problem in the daily practice. It is known that clinically manifested HF represents an independent predictor of mortality in patients starting hemodialysis therapy<sup>14</sup>, but the knowledge of the underlying cause can be important to direct the therapeutic conduct. Some questions, therefore, become relevant in the management of this high-risk population: is there simply volume overload or primary heart disease? In case of cardiopathy, is the systolic and/or diastolic function compromised? Can we estimate LV filling pressures? In this context, the use of technically simple complementary assessment methods, of relative low cost and with good reproducibility brings an important contribution to the development of knowledge of the physiopathology of the disease and the evaluation of potential treatment strategies.</p>
      <p>
        <bold>The Role of Echocardiography</bold>
      </p>
      <p>The diagnosis of LV abnormalities by Doppler echocardiography is an important step for the characterization of individuals with higher cardiovascular risk, estimating the prevalence of primary heart disease in a population to study its predisposing factors, prognostic impact and the effect of therapeutic interventions<sup>15</sup>. The Doppler echocardiogram is a complementary, non-invasive examination, broadly used in the assessment of heart structure and function, bringing several ultra-sound techniques together in a single examination.</p>
      <p>Traditionally, the M-mode and the two-dimensional Doppler echocardiogram allow the assessment of ventricular mass and volumes, with excellent accuracy for the diagnosis of hypertrophy, definition of its geometric pattern (concentric or eccentric) and systolic function estimate (qualitative or quantitatively). Additionally, the techniques derived from the Doppler can generate indirect information regarding the ventricular relaxation and its filling dynamics, which constitute the physiology of diastole. A Canadian study that followed a cohort of 432 patients starting hemodialysis therapy showed that only 16% had a normal Doppler echocardiogram<sup>16</sup>. The finding of echocardiographic alterations, such as hypertrophy, dilatation and systolic dysfunction triples the risk of HF, regardless of age, diabetes and coronary failure<sup>16</sup>.</p>
      <p>
        <bold>Left Ventricular Hypertrophy</bold>
      </p>
      <p>The left ventricular hypertrophy (LVH) is highly prevalent in CKD and is associated to a clearly unfavorable prognosis. More than 2/3 of the patients undergoing dialysis with LVH die of congestive heart failure or sudden death<sup>17</sup>, which is the reason why it is one of the main targets of therapeutic intervention, together with coronary artery disease.</p>
      <p>The incidence of LVH increases with the progressive decline in renal function, with an inverse linear correlation between the LV mass and the glomerular filtration rate<sup>18</sup>. Thus, the prevalence of LVH varies from 16-31% in individuals with CKD and glomerular filtration &gt; 30 ml/min., from 38-45% in those with more compromised renal function<sup>18,19</sup>, from 60-75% in those starting renal substitution therapy, and up to 70-90% in patients undergoing regular dialysis therapy<sup>14,20,21</sup>.</p>
      <p>The LV mass is proportional to body size and, traditionally, the indexation by body surface has been used for this correction in the classic studies. Different values of partition have been employed in several prospective studies to define the presence of LVH. As examples, Silberberg et al<sup>22</sup> used 125 g/m<sup>2</sup> as reference value, whereas Parfrey et al<sup>16</sup> used values employed in the study by Framingham (132 g/m<sup>2</sup> for men and 100 g/m<sup>2</sup> for women). In spite of this variation, all had similar results, demonstrating the clear effect of increased ventricular mass in the adverse prognosis<sup>16,22,23</sup>. However, the individual undergoing hemodialysis is subject to large body weight alterations, either caused by alterations in volemia or by the nutritional status impairment, which can lead to assessment errors based on the indexation by body surface. Thus, the indexation by height to the power of 2.7, proposed by de Simone et al<sup>24</sup>, seems to be the most accurate to estimate LV mass in this group of patients. Applying this concept to patients undergoing hemodialysis, it was demonstrated that the method based on height has a slight superior value for the prediction of general and cardiovascular mortality than the one based on body surface<sup>25</sup>. It is important to recognize that part of the alterations in the LV geometry in uremic patients might be related to the moment when the echocardiogram is performed. Soon after the hemodialysis session, a reduction in the LV diastolic diameter is common as well as increased wall thickness as the pure consequence of the volume depletion by ultrafiltration. Similarly, the assessment carried out right before the hemodialysis session can diagnose LV dilatation with eccentric hypertrophy, which will be "converted" to concentric at the end of the session. Such fluctuations can lead to evaluation errors, which can be minimized by performing the examination on interdialytic days (Tuesday or Thursday), preferably between 12 PM and 6 PM<sup>16</sup>.</p>
      <p>Although the LVH diagnosed at the echocardiogram is a universally acknowledged independent predictor of mortality, it is important to emphasize that this onus is attained after a period of at least two years of dialytic therapy<sup>14</sup>. Additional stratification can be obtained through the categorization of the geometric pattern of the myocardial hypertrophy, that is, whether it is concentric or eccentric<sup>23</sup>. A multicentric prospective study with a cohort of 432 patients starting hemodialysis showed a median time of survival of 48 months for patients with concentric LVH and 56 months for those with eccentric LVH<sup>14,23</sup>.</p>
      <p>The mass monitoring through seriate echocardiogram is an additional clinical tool of great importance for the assessment of prognosis and degree of success of interventions aiming at the regression of the LVH<sup>26</sup>. Evidence indicates that the progression of LVH in individuals with CKD is predictive of cardiovascular events, regardless of the basal LV mass values<sup>27</sup>. On the other hand, the regression of myocardial hypertrophy can be obtained with vigorous pharmacological treatment, especially with angiotensin-II converting enzyme inhibitors, resulting in the decrease in the number of cardiovascular events and longer survival<sup>21</sup>.</p>
      <p>Other LVH regression strategies in terminal CKD, such as the treatment with erythropoietin, restricted control of volemia by aggressive ultrafiltration and renal transplant can also have their effects monitored through echocardiography.</p>
      <p>
        <bold>Left Ventricular Systolic Dysfunction</bold>
      </p>
      <p>In studies using different methodologies, the prevalence of the LV systolic dysfunction varied from 15% to 18% in patients undergoing dialysis (starting the treatment<sup>28</sup> or undergoing regular chronic therapy<sup>29</sup>, respectively), reaching 28% in individuals assessed at the moment of the renal transplant<sup>20</sup>. The LV systolic dysfunction is a powerfully unfavorable prognostic indicator for individuals undergoing hemodialysis<sup>23</sup> as well as for those submitted to renal transplant<sup>20</sup>. The accountable mechanisms are multifactorial, including coronary failure, anemia, hyperparathyroidism, uremic toxins, malnutrition and prolonged hemodynamic overload<sup>30</sup>. The analysis of the LV systolic function by the echocardiogram is performed annually, usually by methods that evaluate the ejection phase, especially the percentage of shortening and ejection fraction (EF). These techniques, based on measurements carried out in the endocardium, can overestimate the contractility in patients with LVH. Alternatively, a method based on the measurement of the myocardial wall shortening fraction, the midwall fractional shortening, proposed as a measurement of the systolic function regardless of the LV geometry<sup>31</sup>, can be used in this context, diagnosing a lower systolic performance in individuals with normal EF.</p>
      <p>In spite of such considerations, the LV systolic function diagnosed by any of the aforementioned methods was independently associated with fatal and non-fatal cardiovascular events, with no difference being demonstrated regarding the predictive power among them<sup>32</sup>.</p>
      <p>It is interesting to mention that, although the adverse effect of the systolic dysfunction is independent from the left ventricular mass, these alterations interact in the prediction of cardiovascular outcomes, with the maximal risk being reached by patients that present an association of both<sup>32</sup>.</p>
      <p>
        <bold>Left Ventricular Diastolic Dysfunction</bold>
      </p>
      <p>The diastolic dysfunction is characterized by alterations in the ventricular relaxation and compliance, frequently coursing with a compensatory increase in the filling pressures at more advanced phases. From a hemodynamic point of view, the increase in the left intraventricular diastolic pressure is the phenomenon responsible for the manifestation of HF, whatever the underlying cause is<sup>33</sup>. Studies of necropsies and experimental uremia pointed to the presence of specific diffuse intermyocardiocytic fibrosis in the heart of uremic individuals, not observed in hypertensive, non-nephropathic individuals, which could imply in electrical instability (predisposing to sudden death) and alterations in the diastolic properties of the myocardium (predisposing to the increase in the filling pressures)<sup>10,34</sup>. Among the physiological mechanisms related to prominent myocardial fibrosis, one can postulate the activation of humoral factors associated to hypertrophy (high plasma levels of angiotensin II, parathyroid hormone, endothelin, aldosterone and catecholamines) and the presence of underlying myocardial ischemia<sup>13,34</sup>. The increase in the stiffness and the decrease in the relaxation (secondary to fibrosis) lead to the exacerbation of the volemic variation effects on the LV filling. Thus, even in patients with normal EF, a small increase in LV volume can generate pulmonary congestion, whereas the volemic depletion can induce the decrease in the chamber filling, causing arterial hypotension and hemodynamic instability<sup>2</sup>. Hence, it is important to adequately assess not only the LV systolic, but also the diastolic function, of which alterations can be triggered by episodes of acute pulmonary edema and intradialytic hypotension<sup>2,35</sup>.</p>
      <p>Studies with small sample sizes reported a prevalence of LV diastolic dysfunction in uremic patients varying from 50 to 65%, including pre-dialysis populations, those undergoing dialysis and post-transplant ones<sup>17</sup>. Although the alterations in LV filling are frequently detected in patients undergoing hemodialysis, the prevalence of diastolic dysfunction and its prognostic meaning are not completely known in this group<sup>13,36</sup>.</p>
      <p>The limitations of the use of Doppler echocardiographic parameters derived from the mitral transvalvular flow in previous studies<sup>14,37</sup>, are due to the fact that these parameters are highly dependent on the pre-load conditions<sup>38-40</sup>. Such approach can produce false-negative results in patients undergoing hemodialysis, diagnosing as normal individuals with a pseudonormalization of the mitral flow (high filling pressures masking the LV relaxation alterations).</p>
      <p>In this context, the Doppler echocardiographic parameters employed in the assessment of cardiac function represent an important advancement regarding diagnosis. In the last years, the tissue Doppler (TD) of the mitral annulus was introduced in the clinical scenario as an important method of assessment of the LV diastolic function, segmental and global. The early diastolic velocity of the mitral annulus (E') is well correlated with the relaxation indices measured by invasive methods<sup>41,42</sup>. Some researchers demonstrated that the diastolic velocities derived from the mitral annulus tissue Doppler (E' and A') are "relatively" independent from the pre-load, presenting no significant variation after a hemodialysis session, providing that certain "physiologic" limits of volemic decrease are respected, that is, that they are incapable of triggering alterations in the heart rate and arterial pressure<sup>39,43</sup>. For that reason, E' seems to be particularly useful in patients undergoing hemodialysis, identifying relaxation alterations independent from the LV filling pressures and, consequently, differentiating the pseudonormalization from the actual normal pattern of diastolic function<sup>39</sup>. A recent Australian study followed a cohort of 129 patients with terminal CKD (with no evidence of LV ischemia at the stress echocardiogram) for more than 2 years, demonstrating that the tissue diastolic velocity added an independent prognostic value to the clinical parameters<sup>44</sup>. The ratio between the early diastolic velocity of the mitral flow (E) and E' (known as the E/E' ratio) was the best non-invasive predictor of increase in the filling pressures in the comparison of multiple Doppler echocardiographic indices with the final diastolic pressure (measured by hemodynamic catheter), either by using the septal E'<sup>45</sup> or the mean between the septal and the lateral E'<sup>46</sup>. Hence, the E/E' ratio is an especially interesting index for the diagnosis of advanced diastolic dysfunction. The possibility of indicating an increase in intraventricular pressure through this method allowed, in parallel, the demonstration of its important prognostic value in two recent studies with terminal CKD patients. A study carried out with 125 candidates to renal transplant demonstrated that the E/E' &gt; 15 was an independent predictor of the increase in the LV diastolic pressure (&gt; 15 mmHg) and was associated to a higher general mortality in this group<sup>47</sup>.</p>
      <p>Another study of 220 individuals with terminal CKD followed for 4 years, concluded that the E/E' ratio was an independent predictor of general and cardiovascular mortality, adding prognostic information above and beyond the clinical and biochemical data, ventricular mass and systolic function<sup>48</sup>.</p>
      <p>
        <bold>Left Atrial Dilatation</bold>
      </p>
      <p>Strong evidence indicates the left atrium (LA) dilatation as a robust predictor of cardiovascular outcomes in the general population and in several clinical scenarios<sup>49</sup>. Recent directives recommend that the adequate quantification of the LA size be obtained by the estimate of the chamber volume in the two-dimensional mode and not by the traditional measurement of the anteroposterior diameter in the M-mode<sup>50,51</sup>. In addition to being superior in the prediction of cardiovascular events (including atrial fibrillation, cerebrovascular accident, heart failure, myocardial infarction and cardiac death<sup>52</sup>), the LA volume is related to the severity and duration of the LV diastolic dysfunction<sup>53</sup>. Differently from the elevated indices derived from the conventional (mitral flow) or tissue Doppler (mitral annulus), which provide momentary and transient information on the left ventricular filling, the LA volume functions as a chronic marker of the diastolic function, reflecting the "historical" mean of the increased filling pressures<sup>53</sup>. A recent study with hemodialysis patients in sinus rhythm and no mitral valvulopathy demonstrated that the LA volume indexed for body surface &gt; 35 ml/<sup>2</sup> was the most accurate parameter for the detection of pseudonormalization of the mitral flow in comparison with the several indices that were previously tested<sup>54</sup>. Extending the clinical value of the LA, two recent publications, using different indexation methods (body surface<sup>29</sup> or height to the power of 2.7<sup>55</sup>), found that the index was an independent predictor of mortality in patients receiving substitutive renal therapy. The finding of the indexed LA volume &gt; 32 ml/m<sup>2</sup> provided complementary information to the traditional clinical and echocardiographic data, including EF, E/E' ratio and left ventricular mass<sup>29</sup>. Although new observational and interventional studies are needed to validate these findings and to define the best indexation method in patients with nephropathies, it is advisable that the measurement of the LA be incorporated to the routine echocardiographic assessment of these patients, considering that the consensus of the American Society of Echocardiography recommends it for the general population<sup>51</sup>. As the LV diastolic function seems to be chronically compromised in most patients undergoing hemodialysis, even in those who are asymptomatic<sup>13</sup>, the LA volume can offer the opportunity to identify the individuals at higher risk to present HF, atrial arrhythmias and poor clinical evolution.</p>
      <p>
        <bold>Valvular Calcifications</bold>
      </p>
      <p>The calcification of cardiac valves is frequent in patients chronically treated with dialysis. Some data suggest that the valvular calcification is not only a consequence of natural aging and calcium-phosphorus metabolism disorders, but also caused by inflammation, similar to what is seen in atherosclerosis<sup>56</sup>. In addition to presenting a clinical effect by determining valvular stenosis and/or reflux, its importance lies in the association that has been reported between the valvular calcification and higher risk of mortality and cardiovascular events in the uremic patient. A study carried out in 192 patients undergoing peritoneal dialysis found calcification in at least one valve, mitral or aortic, in 32% of the population<sup>57</sup>. After a mean follow-up of 18 months, the cardiovascular mortality was 22% <italic>versus</italic> 3% in individuals with and without valvular calcification, respectively. Such association was independent from the usual clinical and demographic variables, C-reactive protein and concomitant atherosclerotic vascular disease<sup>57</sup>.</p>
      <p>Another interesting study proposed a score for prognosis prediction after renal transplant based on the echocardiogram. After the follow-up of 203 transplanted patients (mean age 47 &#177; 12 years, 93% undergoing dialysis), independent predictors of mortality were age <underline>&gt;</underline> 50 years, LV systolic dimension <underline>&gt;</underline> 35 mm, wall thickness <underline>&gt;</underline> 14 mm and presence of calcification in the mitral annulus<sup>58</sup>. Patients aged <underline>&gt;</underline> 50 years and two of the other three predictors had a 5-year mortality of 82%<sup>58</sup>. In contrast to these findings, a study carried out with 202 patients undergoing hemodialysis (with a prevalence of 23% of valvular calcification) did not demonstrate an independent prognostic value after adjustment for risk factors and LV mass<sup>59</sup>.</p>
      <p>
        <bold>Pericardial Disease</bold>
      </p>
      <p>Acute pericarditis can occur in approximately 20% of the uremic patients, before the start of dialysis or during the chronic dialysis treatment<sup>60</sup>. Uremia and/or inefficient dialysis are the most frequent causes. Individuals undergoing maintenance hemodialysis with significant pericardial effusion usually do not respond satisfactorily to the intensification of the dialysis and may be referred to early elective pericardial drainage with the objective of preventing hemodynamic complications<sup>61</sup>. Constrictive pericarditis occurs less frequently in patients undergoing hemodialysis.</p>
      <p>
        <bold>Stress Echocardiography</bold>
      </p>
      <p>The use of pharmacological stress echocardiography in patients with terminal CKD is an attractive strategy, as it allows the assessment of myocardial ischemia without demanding from the patient the capacity to exercise and, moreover, it provides the estimate of the LV basal systolic function. Furthermore, the presence and extension of the ischemia during the assessment have a prognostic value that is independent for general mortality in this group of individuals<sup>62</sup>. A larger volume of evidence was generated with the use of dobutamine as the stressor agent. The set of available information does not indicate significant differences in accuracy and negative predictive value in comparison to Nuclear Medicine when assessing obstructive coronary disease in candidates to renal transplant (including those undergoing dialysis)<sup>63,64</sup>. Alternatively, two small studies suggested the usefulness of the stress echocardiogram with dipyridamole in the diagnosis of ischemia<sup>65</sup> and the prognosis prediction<sup>66</sup>. Although patients with CKD and normal stress echocardiogram results have a better prognosis than those with abnormal results, the mortality rate remains considerable in the first group<sup>62</sup>, when compared to the excellent prognosis conferred by the normal test results in the general population. This can be explained by the high-risk profile inherent to the individual with nephropathy. Moreover, a national study showed that the assessment has a limited sensitivity in the presence of coronary uniarterial disease and obstructions between 50 and 70% of the vessel lumen<sup>67</sup>. Thus, an individualized approach must be considered in individuals at higher risk, as the coronary angiography can still be of crucial importance in the detection of clinically relevant coronary artery disease<sup>64</sup>.</p>
      <p>
        <bold>Conclusion</bold>
      </p>
      <p>The set of evidence indicates the extraordinary role of the Doppler echocardiography in the improvement of the global clinical assessment quality of the patient with CKD undergoing dialysis. The literature and the clinical practice have emphasized the usefulness of the method in the diagnosis of subclinical heart dysfunction, in the refinement of the clinical diagnosis of heart failure, in the cardiovascular risk prediction and when establishing the course and follow-up of the treatment strategies. The Doppler echocardiographic outcomes have shown to be useful substitute markers for prognosis and intervention studies. North-American directives recommend the Doppler echocardiogram for all patients undergoing dialysis one to three months after the start of the substitutive renal therapy and at three-year intervals subsequently, regardless of symptoms<sup>68</sup>. Our opinion is that all patients initiating dialytic therapy must be submitted to an echocardiogram. However, shorter intervals between evaluations can be of clinical value in individualized therapies. It has been demonstrated that the follow-up with seriate echocardiograms adds prognostic value beyond the basal assessment, enabling the monitoring of the regression or not of the LV alterations<sup>26</sup>. In the future, new Doppler echocardiographic methods with the capacity to investigate subclinical myocardial disease (such as strain, strain rate and ultrasonic tissue characterization) will further benefit this group of patients at excessive cardiovascular risk.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This study is not associated with any post-graduation program.</p>
      <p>
        <bold>Refer&#234;ncias</bold>
      </p>
    </body>
  </sub-article>
</article>
